Drug, bio-affecting and body treating compositions inventions 02/08

20080050309 - Compositions of pharmaceuticals for use in low energy neutron therapy: A saccharide with a ring sulfur atom can participate more readily in biological processes than a sugar with a ring oxygen atom, and such thiosaccharides possess unique physiochemical properties that include penetration of a viscous lipid bilayer membrane of a cancer cell, and resistance to reduction by enzymes, enabling retention... Agent: Zbigniew Janusz Witczak

20080050314 - Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b): The invention provides a human GSK3B which is associated with cardiovascular diseases, cancer, metabolic diseases, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, metabolic diseases, hematological diseases, inflammation,... Agent: Banner & Witcoff, Ltd.

20080050315 - Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1): The invention provides a human PRKG1 which is associated with cardiovascular diseases, respiratory diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hemato-logical diseases, muscle-skeleton-diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular... Agent: Banner & Witcoff, Ltd.

20080050313 - Sulfs as modifiers of the beta-catenin pathway and methods of use: Human SULF genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of SULF are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080050322 - Photostable cosmetic compositions: Photostable cosmetic compositions comprising sunscreens, more particularly to cosmetic compositions comprising dibenzoylmethane sunscreens are provided. It is known that dibenzoylmethane and its derivatives are relatively sensitive to ultraviolet radiation and they decompose rapidly under the effect of sunlight. This decomposition is accelerated in the presence of UV-B sunscreens, especially p-methoxycinnamic... Agent: Unilever Intellectual Property Group

20080050320 - Skin care compositions containing a hydrophobic material and related methods: The invention includes a skin care composition comprising an acrylate polymer; a yield value-increasing polymer; and a non-silicone hydrophobic material. The composition has a yield value of at least about 4. Also included within the scope of the invention are related methods, such as methods of depositing a hydrophobic material... Agent: Colgate-palmolive Company

20080050323 - Sunscreen composition: e

20080050318 - Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines: Disclosed herein is a composition for topical application to skin, comprising, in a physiologically acceptable medium (i) at least one peptide comprising at least one amino acid sequence derived from the amino acid sequence of the protein SNAP 25, and (ii) at least one calcium-channel inhibitor. Further disclosed is the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080050326 - Deodorant composition comprising linalool and dihydromyrcenol: A deodorant composition comprising: a) a fragrance system comprising a fragrance material, and a combination of linalool and dihydromyrcenol, wherein the combination of linalool and dihydromyrcenol is included in the composition in an amount from about 0.2% to about 1% by weight of the composition, and wherein the ratio of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080050330 - Aqueous hair cosmetic composition: d

20080050331 - Cosmetic composition containing a protease activator: An exfoliation composition comprising a protease activator such as a chestnut extract, at least one exfoliator and a cosmetically acceptable vehicle, and methods of use thereof.... Agent: The Estee Lauder Cos, Inc

20080050332 - Method of skin care and/or treatment using glutaredoxin: Methods for the prevention and treatment of skin damage arising from the exposure to UV radiation, air pollution and other stressors capable of leading to the formation of free radicals, using the small-dithiol protein glutaredoxin in a dermatologically acceptable carrier that can be applied topically are disclosed. Some embodiments may... Agent: Hannah Naomi Sivak

20080050333 - Oil-in-water dispersion: t

20080050329 - Composition for coating keratin fibres comprising a block polymer and fibres: A subject of the invention is a composition for coating keratin fibres comprising, in a cosmetically acceptable medium, a block polymer and fibres. A subject of the invention is also the use of such a composition for obtaining a makeup for the keratin fibres, in particular the eyelashes, which is... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080050334 - Cosmetic composition comprising an extract of emblica officinalis, a hydroxy acid, and an n-substituted aminosulfonic acid, and methods of using same: A cosmetic composition useful for the depigmentation of skin containing an extract of Emblica officinalis, at least one hydroxy acid, and at least one N-substituted aminosulfonic acid having the structural formula (I):... Agent: L'oreal Usa/ Patent Department

20080050336 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080050350 - Method for introducing an exogenous gene into a stem cell: The subject invention relates to a method for introducing an exogenous gene into a stem cell, which comprises introducing the exogenous gene into the stem cell under specific electroporation conditions. The invention also relates to a stem cell stably expressing an exogenous gene, a transgenic animal and a pharmaceutical composition.... Agent: Ladas & Parry

20080050353 - Quality of life for hepatitis c patients with a formulation for administration to the oral mucosa including lactobacillus delbrueckii subsp. bulgaricus and n-acetyl d-glucosamine: Disclosed are quick dissolve tablets, each including Lactobacillus delbrueckii subsp bulgaricus (LBD) and N-acetyl-glucosamine (NAG), as well as excipients, for oral mucosal administration, for improving the quality of life of Hepatitis C patients. Any formulation suitable for oral mucosal administration can be employed for administering the active ingredients in a... Agent: Eric Mirabel

20080050310 - Antibodies and immunoconjugates and uses therefor: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.... Agent: Genentech, Inc.

20080050311 - Monoclonal antibody hpam4: This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or... Agent: Faegre & Benson LLP Patent Docketing

20080050312 - Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents: This invention relates to a method of imaging vesicular monoamine transporters and to labeled compounds and pharmaceutical compositions thereof, and methods of making labeled compounds useful in imaging vesicular monoamine transporters. This invention also relates to compounds, and methods of monitoring progression of a disease related to vesicular monoamine transporters.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080050316 - Molecular imaging of epithelial cells in lymph: Methods and imaging agents for imaging epithelial cancer cells in the lymphatic system are disclosed herein. In an embodiment, an imaging agent for imaging cancer cells in a lymphatic system comprises a fluorescent dye conjugated to one or more antibodies. The antibodies are capable of specific binding to an epithelial... Agent: Conley Rose, P.C. David A. Rose

20080050317 - Oleaginous pharmaceutical and cosmetic foam: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein... Agent: Wilmerhale/boston

20080050319 - Benzylidene-alpha-dicarbonyl compounds as novel uv absorbers: as UV filters in cosmetic formulations, in particular in combination with UV filters from the group consisting of methoxycinnamate derivatives and/or dibenzoylmethane derivatives, with the proviso that R5 is H if R4 is COR, is described.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20080050321 - Formulations with feruloyl glycerides and methods of preparation: X1 and X2 are the same or different, and at least one of X1 or X2 is a functional group that bonds with the compound comprising at least one UV-absorbing chromophore, and b+f≧2; Y comprises an O, N, or S that is substituted or unsubstituted; each a, b, c, e... Agent: Banner & Witcoff, Ltd.

20080050324 - Method of applying makeup by means of a magnetic composition including at least one differactive pigment: The present invention relates to a method of applying makeup to keratinous substances, in particular the skin, the lips, the nails, or hair, the method comprising the following steps: depositing at least one cosmetic composition on the surface to be made up, the cosmetic composition comprising: bodies that present non-zero... Agent: Oliff & Berridge, PLC

20080050325 - Cosmetic composition with paramagnetic material: Cosmetic composition with paramagnetic material is described. In embodiment(s), a cosmetic composition can include a paramagnetic material in a cosmetic medium where the combination forms a cosmetic application, a lipstick, a lotion, a blush, or other similar application. The paramagnetic material can be included in a quantity sufficient to effectuate... Agent: Sadler, Breen, Morasch & Colby, P.s.

20080050327 - Body care composition with water-soluble abrasive particles: The invention relates to a body care composition, in particular a cosmetic body care composition, more particularly a body cleaning material, comprising solid particles, which are moderately soluble in water. A most preferred embodiment of the present invention is a peeling shampoo.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080050328 - Cosmetic compositions with silicone resin polymers: A cosmetic composition containing a silicone resin polymer comprised of M units in combination with Q or T units or both, wherein the number of M units is greater than the number of Q units or T units or combination thereof, and a method for improving the finish of a... Agent: Julie Blackburn Revlon Consumer Products Corporation

20080050335 - Ophthalmic solutions: Aqueous ophthalmic solutions containing a combination of hyaluronic acid or a pharmaceutically acceptable salt thereof, e.g. sodium hyaluronate, and polyvinyl alcohol are disclosed. These solutions have a synergistic effect on viscosity and provide a statistically significant improvement over the prior art formulations. The solutions are used as artificial tear for... Agent: Innovar, LLC

20080050337 - Method for using calcium-sensitive potassium channel agonist for delivering a medicant to an abnormal brain region and/or a malignant tumor: Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel activator (other than bradykinin or a bradykinin analog), such as NS-1619, EBIO, a... Agent: Davis Wright Tremaine LLP/los Angeles

20080050338 - Stable liquid interferon formulations: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080050339 - Stable liquid interferon formulations: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080050340 - Cd40 agonist antibody /type 1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided.... Agent: Hunton & Williams LLP Intellectual Property Department

20080050343 - Adeno-associated virus serotype i nucleic acid sequences, vectors and host cell containing same: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.... Agent: Howson And Howson

20080050341 - Adoptive immunotherapy with enhanced t lymphocyte survival: The invention provides for compositions, e.g., pharmaceutical compositions, comprising a T lymphocyte, or a population thereof, expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response. The invention further provides an isolated T lymphocyte, or population thereof, expressing... Agent: Leydig, Voit & Mayer, Ltd.

20080050342 - Genetic inhibition by double-stranded rna: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of... Agent: Morgan Lewis & Bockius LLP

20080050349 - Cell based therapy for the pulmonary system: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.... Agent: Ridout & Maybee Suite 2400

20080050351 - Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorder: The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, reproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native... Agent: Pfizer Inc.

20080050352 - Pharmaceutical composition comprising botulinum, a non ionic surfactant, sodium chloride and sucrose: The invention relates to a solid or liquid pharmaceutical composition comprising botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A, B, C, D, E, F or G), and a surfactant. In particular the invention relates to a solid or liquid... Agent: Jacobson Holman PLLC

20080050354 - Protecting bioactive food ingredients using microorganisms having reduced metabolizing capacity: The invention concerns a food product containing living microorganisms and bioactive food ingredients of interest, wherein the living microorganisms and the bioactive food ingredients of interest are organized so as to reduce metabolizing of said bioactive ingredients by said living microorganisms. More particularly, the invention concerns the use therefor of... Agent: Foley And Lardner LLP Suite 500

20080050355 - Protection of bioactive food ingredients by means of encapsulation: The invention relates to a food product containing one or more live micro-organisms and at least one bioactive food ingredient of interest, in which the bioactive food ingredient(s) of interest is protected by means of encapsulation in a fat, such as to reduce the metabolisation thereof by the aforementioned live... Agent: Foley And Lardner LLP Suite 500

20080050344 - Biological control of plant diseases: The present invention relates to the use of Ulocladium oudemansii as a biological control agent. Processes and compositions for the biological control of Botrytis species using Ulocladium oudemansii are also provided.... Agent: Jacobson Holman PLLC

20080050345 - Adeno-associated virus serotype i nucleic acid sequences, vectors and host cells containing same: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.... Agent: Howson And Howson

20080050346 - Elastin producing fibroblast formulations and methods of using the same: The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests... Agent: Pepper Hamilton LLP

20080050348 - Method and composition for repairing heart tissue: A method of expanding blood stem cells for the repair of heart tissue and/or function, and compositions resulting from the expansion method in a rotating bioreactor. This invention also relates to a method of TVEMF-expanding blood stem cells for the repair of heart tissue and/or function, and compositions resulting from... Agent: Ladas & Parry LLP

20080050347 - Stem cell therapy for cardiac valvular dysfunction: Disclosed are methods, compounds and compositions useful for treatment of a patient with valvular dysfunction. The invention relates to using stem cells, modified stem cells, derivatives thereof, and agents stimulatory to stem cells in order to substantially ameliorate, and in some cases induce a therapeutic benefit, to a patient suffering... Agent: Knobbe Martens Olson & Bear LLP

20080050356 - Pharmacological vitreolysis: Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited... Agent: Wilmerhale/boston

20080050358 - Identification of snps associated with hyperlipidemia, dyslipidemia and defective carbohydrate metabolism: The present invention relates to a nucleic acid molecule comprising a chromosomal region contributing to or indicative of hyperlipidemias and/or dyslipidemias or defective carbohydrate metabolism, wherein said nucleic acid molecule is selected from the group consisting of: (a) a nucleic acid molecule having or comprising the nucleic acid sequence of... Agent: Birch Stewart Kolasch & Birch

20080050357 - Systems and methods for antibody engineering: Methods, computer systems, and computer program products for antibody engineering. A variant set for an antibody of interest is constructed by identifying, using a plurality of roles, a plurality of positions in the antibody of interest and, for each respective position in the plurality of positions, substitutions for the respective... Agent: Jones Day

20080050360 - Method of treating a pathological syndrome and a pharmaceutical agent: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms... Agent: Houston Eliseeva LLP - Ru

20080050362 - Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells: The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080050363 - Novel nucleic acid molecules encoding opioid growth factor receptors: This invention relates to novel nucleic acid molecules coding for opioid growth factor receptors. In particular, the present invention provides isolated nucleic acid molecules coding for human and rat OGF receptors. Antisense molecules, expression vectors and host cells, isolated proteins encoded by such nucleic acid molecules, antibodies directed against such... Agent: Scully Scott Murphy & Presser, PC

20080050359 - Production of anti-self antibodies from antibody segment repertoires and displayed on phage: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface... Agent: Howrey LLP

20080050361 - Staphylococcus aureas specific anti-infectives: The present invention provides novel anti-infectives that act on Staphylococcus aureus (S. aureus) iron-regulated surface determinants, IsdA, IsdB, IsdC, IsdH (or HarA).... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080050364 - Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist: A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on... Agent: Genentech, Inc.

20080050365 - Anti-hiv antibody: The present invention aims at providing a high affinity anti-HIV antibody. According to the present invention, there are provided an antibody or a fragment thereof that binds to the gp12 glycoprotein of HIV and has a dissociation constant (KD) value of 1.0×10−9 (M) or less; a pharmaceutical composition comprising the... Agent: Birch Stewart Kolasch & Birch

20080050368 - Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering... Agent: Foley Hoag, LLP/wyeth Patent Group, (w/wys)

20080050375 - Binding compositions: related reagents: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for thereaputic purpose are also provided.... Agent: Eli Lilly & Company

20080050371 - Cd16a binding proteins and use for the treatment of immune disorders: CD16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.... Agent: King & Spalding

20080050367 - Humanized antibodies that recognize beta amyloid peptide: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.... Agent: Lahive & Cockfield, LLP

20080050372 - Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis: α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances insulin signal transduction and increase whole-body insulin sensitivity. Therefor, AHSG and its gene(s) are useful targets for agents that inhibit the development or progression of Type... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080050366 - Neutralizing antibodies and methods of use thereof: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080050374 - Novel antigen-binding polypeptides and their uses: Novel antigen-binding polypeptides (ABP) and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080050370 - Stabilized polypeptide compositions: The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.... Agent: Lahive & Cockfield, LLP

20080050369 - Therapeutic applications of t-bam (cd40l) technology to treat diseases involving smooth muscle cells: Activation of smooth muscle cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the smooth muscle cells with an anti-T-BAM (CD40L) antibody capable of inhibiting the interactions between CD40 ligand and the CD40-bearing smooth muscle cells, in an amount effective to inhibit activation of the... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080050373 - Treatment with anti-erbb2 antibodies: The present invention concerns the treatment of cancer with anti-ErbB2 antibodies.... Agent: Genentech, Inc.

20080050376 - Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells: The present invention discloses antibodies, antigen binding fragments, peptides and peptidomimetics immunoreactive with provasopressin and compositions thereof, methods of phenotyping tissue samples, methods of treating cancer, and kits for phenotyping test biopsy samples and bodily fluids for breast cancer, small cell lung cancer, ductal carcinoma in situ, and atypical ductal... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080050377 - Compositions and methods relating to stop-1: The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind... Agent: Genentech, Inc.

20080050378 - Method for diagnosing non-small cell lung cancer: Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.... Agent: Townsend And Townsend And Crew, LLP

20080050379 - Cancer gene determination and therapeutic screening using signature gene sets: Processes for assaying potential antitumor agents based on their modulation of the expression of specified genes, or sets, of suspected cancer cell genes are disclosed, along with methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, or sets... Agent: Alan J. Grant, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080050380 - Glycoprotein vi and uses thereof: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080050381 - Antihuman baff antibody: An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080050382 - Granulysin and uses thereof: Disclosed are uses of granulysin in methods of diagnosing or treating autoimmune disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080050383 - Immunotherapy for clearing pathological tau conformers: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed... Agent: Nixon Peabody LLP - Patent Group

20080050386 - Novel proteins, gene encoding the same and method of utilization thereof: The present invention provides, as a gene encoding an antigen recognized by G-CSF-inducing antibodies, a gene encoding: (a) a protein having the amino acid sequence listed as SEQ ID NO:2 of the Sequence Listing; (b) a protein having the amino acid sequence listed as SEQ ID NO:2 of the Sequence... Agent: Birch Stewart Kolasch & Birch

20080050384 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080050385 - Tumor therapy with an anti-vegf antibody: The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080050387 - Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor: Disclosed are compositions and methods for modulating AR activity, such as non-androgen dependent AR activity. Also disclosed are compositions and methods for diagnosing beast cancer and for inhibiting breast cancer growth. In addition, disclosed are methods for identifying molecules that inhibit AR in non-androgen dependent ways.... Agent: Needle & Rosenberg, P.C.

20080050388 - Humanized collagen antibodies and related methods: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic... Agent: Wilson Sonsini Goodrich & Rosati

20080050389 - Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.... Agent: Howson And Howson

20080050390 - Administration of gamma globulins to treat metastatic melanoma: This invention relates to cancer therapy and in particular to the administration of gamma globulins to inhibit both primary tumor and metastasis and augment treatment of primary cancerous tumors. In accordance with this invention, the treatment of various cancerous diseases is accomplished by administering a preparation containing intact gamma globulins... Agent: Pearl Cohen Zedek Latzer, LLP

20080050391 - Method for treating autoimmune diseases with antibodies: A method for treating autoimmune diseases in a mammal which method comprises administering to the mammal an effective amount of at least one antibody specific for a soluble antigen is provided. Furthermore, a novel mechanism of action has been established in accordance with the present invention for antibody-based treatment regimes... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080050392 - Method of treating a pathological syndrome and a pharmaceutical agent: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms... Agent: Houston Eliseeva LLP - Ru

20080050393 - Novel nucleic acids and polypeptides: The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.... Agent: Nuvelo, Inc

20080050394 - System and device for medically treating an individual: A system for medically treating/vaccinating an individual comprising a first syringe, containing an anticoagulant material therein, for drawing a sample of blood from the individual. A centrifuge means for centrifuging the sample of blood contained within the first syringe to obtain a buffy coat. A second syringe comprising a second... Agent: James Ray & Associates

20080050395 - Methods for preparing and delivering adjuvant compositions: Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin and a polymer. The polymer is preferably polyacrylic acid-based and the delivery method involves administering a vaccine, including an antigen and the adjuvant, to a mucosal surface.... Agent: Stites & Harbison PLLC

20080050396 - Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients: The present invention relates to proteins belonging to the Bcl-2 family and peptides fragments thereof for use in pharmaceutical compositions. The disclosed proteins and peptide fragments are in particularly useful in vaccine compositions for treatment of cancer. The invention furthermore relates to methods of treatment using said compositions. It is... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080050397 - Multiple antigenic agents and methods for using the same: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections. The multiple antigenic agents of the invention contain at least one of a B cell determinant, a T cell determinant, or a targeting molecule attached to a core peptide composed of Lys-Gly... Agent: Licata & Tyrrell P.C.

20080050398 - Composition comprising beta-defensin 2: The invention relates to compositions comprising at least one peptide with a structure or structural pattern of β-defensin 2 and/or its derivatives, especially human β-defensin 2. The compositions are selected in particular from cosmetic and/or pharmaceutical compositions, cleaning and/or washing agents, water-treatment agents and cooling lubricants. The invention also relates... Agent: Woodcock Washburn LLP

20080050399 - Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins: This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can... Agent: Fish & Richardson PC

20080050400 - Method of accelerating the growth and development of trees and shrubs via enhanced root development: A method of developing seedlings includes germinating the seeds and air pruning the seedlings to a depth of about 3 inches.... Agent: B. Jefferson Boggs Bingham Mccutchen, LLP

20080050401 - Rescue of influenza virus: The invention relates to the field of influenza vaccine production. Influenza vaccines have been produced in embryonated hens' eggs for over 50 years, but recently there have been considerable efforts to develop cell culture systems for vaccine production. The invention provides a nucleic acid comprising an influenza gene segment and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080050402 - Attenuated influenza ns1 variants: Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating... Agent: Robins & Pasternak

20080050403 - Production of viruses, viral isolates and vaccines: The present invention discloses methods for producing and/or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle.... Agent: Trask Britt

20080050404 - Pressure sore treatment: Methods for treating a pressure sore or for preventing development of a pressure sore by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a pressure sore or to a pressure point, or to the vicinity thereof.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080050405 - Ringworm vaccine: A ringworm vaccine is disclosed comprising antigen isolated from at least one dermatophyte and a suitable carrier. The “antigen” can include a single antigen from a dermatophyte or a plurality of antigens as long as at least one antigen is included which will produce a sufficient immune response to confer... Agent: Crowell & Moring LLP Intellectual Property Group

20080050406 - Modified mite allergen and pharmaceutical uses thereof: The present invention provides a modified Dermatophagoides pteronyssinus allergen Der p 5 protein which has ability to inhibit IgE binding when exposed against to the antigen. A method for treating allergy comprising administrating a therapeutically effective dose of the modified D. pteronyssinus allergen Der p 5 protein to a subject... Agent: Banner & Witcoff, Ltd.

20080050408 - Dental whitening compositions: A whitening system has a de-sensitizing effect as well as re-mineralizing capability. The system may be a one-component or a two-component composition. The system may also be an unfoamed, a foamed or a foamable composition. For a one-component system, a sparingly soluble calcium phosphate salt may be in dry particle... Agent: Discus Dental Impressions, Inc.

20080050407 - Oral care products comprising buffer systems for improved mineralization/remineralization benefits: Oral products for the improved mineralization/remineralization of teeth are provided. In an embodiment, the present disclosure provides an oral product comprising a calcium salt, a phosphate salt, a sodium salt and a potassium salt. For example, the molar ratio of the sodium salt to the potassium salt ranges from about... Agent: Bell, Boyd & Lloyd LLP

20080050409 - Water based clear sunscreen and insect repellent composition: A clear, water based, homogeneous insect repellent sunscreen composition, comprising an oil soluble hydrophobic sunscreen component, an amido insect repellent component, an alcohol component, and water.... Agent: Charles J. Zeller, Esq. Avon Products Inc.

20080050410 - Self-decontaminating surface coatings and articles prepared therefrom: The present invention is directed toward a self-decontaminating surface coating, which when cured has a partially hydrophobic surface. The coating comprises a polymeric coating resin which, when cured, is hydrophilic. The coating also comprises a biocide, a germinating agent, and a hydrophobic micro/nano particulate material. The coating is suitable for... Agent: Joy L Bryant, P.C.

20080050411 - Texas game draw: The present invention is a game attractant comprised of a mixture of rice bran, wheat bran and dried molasses to attract the attention of ungulates and avian fauna. By the incorporation of these three ingredients, the nutritional and vitamin value is elevated above the natural diet of the fauna. Therefore... Agent: Jon David Rudo

20080050412 - Antimicrobial implant: A method of building an orthopedic implant including the steps of mixing a powder having antimicrobial properties with a biocompatible powder to form a mixture. Next, the mixture is deposited on top of a substrate. The substrate may be part of the finished product or only a work platform. The... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080050413 - Medical stent provided with a combination of melatonin and paclitaxel: A stent is provided with a composition which includes melatonin and paclitaxel for use in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular vessels.... Agent: Knobbe Martens Olson & Bear LLP

20080050415 - Polymeric/ceramic composite materials for use in medical devices: According to an aspect of the invention, implantable or insertable medical devices are provided, which contain one or more composite regions. These composite regions, in turn, contain (a) a polymeric component comprising a vinyl aromatic polymer and (b) a ceramic component comprising a metal or semi-metal oxide.... Agent: Mayer & Williams PC

20080050416 - Bone delivery device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20080050414 - Methods for treating or preventing restenosis and other vascular proliferative disorders: Described herein is the use of ribonucleotide reductase inhibitors in the prevention or treatment of restenosis and other vascular proliferative disorders.... Agent: Needle & Rosenberg, P.C.

20080050417 - Alginate coated, collagen matrix cellular device, preparative methods, and uses thereof: The present invention is directed to cellular devices comprising a collagen matrix, cell layer, and gelled alginate layer, processes for producing the devices, methods of implanting the devices, and methods of treatment thereof.... Agent: Patent Administrator Fmc Corporation

20080050418 - Medical devices for the release of therapeutic agents: According to one aspect of the invention, medical devices are provided which contain the following: (a) an interior region that contains at least one degradation promoting agent and (b) an exterior region disposed over the interior region that contains at least one biodegradable polymer and at least one therapeutic agent.... Agent: Mayer & Williams PC

20080050419 - Epoxy-containing poly(ester amides) and method of use: The invention provides aliphatic epoxy-containing PEA polymer compositions with film-forming properties. The aliphatic epoxy di-acids used in the invention PEA compositions include non-toxic fatty aliphatic epoxy homologs. A second, C-protected L-lysine-based monomer can be introduced into the polymer to provide additional chain flexibility. The invention PEA polymer compositions are useful... Agent: Dla Piper US LLP

20080050420 - Methods for reducing neovascularization or edema: Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Allergan, Inc.

20080050421 - Methods for reducing neovascularization or edema: Drug delivery devices for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Allergan, Inc.

20080050422 - Method of administering a film product containing a drug: The invention relates to a fast-dissolving film product containing at least one drug; and a water soluble polymer composition. The invention further relates to methods of administering the film product. The method includes administering the film to the oral cavity of a subject in need of the drug; and administering... Agent: Hoffmann & Baron, LLP

20080050423 - Biopolymer-bioengineered cell sheet construct: The present invention discloses a biopolymer-bioengineered human corneal endothelial cell (HCEC) sheet construct for reconstructing corneal endothelium in a patient. The construct includes a biopolymer carrier which is bioresorable and deformable; and a bioengineered cell sheet comprising a monolayer of interconnected HCECs with substantially uniform orientation, wherein the bioengineered cell... Agent: Bacon & Thomas, PLLC

20080050424 - Transdermal therapeutic system for treating parkinsonism: A transdermal therapeutic system (TTS) comprises a silicone-based polymer adhesive system having distributed therein (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol free base in an amount of about 5% to 40% by weight. The adhesive system comprises a silicone adhesive and an additive having increased solubility for the active substance, in an amount effective to increase... Agent: Harness, Dickey, & Pierce, P.l.c

20080050425 - Combination chemotherapy comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex: The present invention relates to methods for treating cancer comprising administering a combination of 5-fluorouracil or a derivative thereof and a liposomal platinum complex. Pharmaceutical compositions comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex, and kits comprising unit doses of 5-fluorouracil or a derivative thereof and liposomal... Agent: Jones Day

20080050426 - Method for preparing extract from wild ginseng showing anticancer activity and the composition comprising the same: The present invention relates to a method for preparing purified extract from wild ginseng showing anticancer activity such as inhibitory of cancer cell adherence, inhibitory of cancer cell metastasis and immunostimulating effect and a composition comprising the same prepared by inventive method. The composition have potent anticancer activity, therefore, it... Agent: Kirk Hahn

20080050427 - Analgesic combination of tramadol and meloxicam: Disclosed is a pharmaceutical composition, comprising a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of oxycodone or a pharmaceutically acceptable salt thereof, said combination in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method... Agent: Davidson, Davidson & Kappel, LLC

20080050428 - Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient: The invention relates to novel extended release dosage forms for reversible proton pump antagonists comprising a basic excipient.... Agent: Nath & Associates PLLC

20080050429 - Low flush niacin formulation: The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment.... Agent: Kos Pharmaceuticals, Inc.

20080050430 - Pharmaceutical compositions and methods for improved bacterial eradication: A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080050431 - Sustained release formulations of oxymorphone: Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.... Agent: Wilmerhale/boston

20080050432 - Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors: The present invention relates to a combined pharmaceutical formulation, which is such designed that the release of each ingredient may be controlled to a predetermined release rate by applying the principle of the so-called chronotherapy, where drugs are administered in such a way that the activities of the drugs are... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080050433 - Water-soluble films for releasing active substances: The invention relates to a water-soluble film for releasing active substances, particularly plant protection products and plant growth promoting substances. The water-soluble film can be defined with regard to its dimensions so that the content of the active substance can be exactly pre-dosed in such a defined film section. The... Agent: Frommer Lawrence & Haug

20080050434 - Novel composition for topical delivery: Pharmaceutical composition for topical administration comprising of at least one active ingredient, its salts, esters, hydrates or derivatives; a gelator system consisting of a fiend of surfactants, a solvent system comprising at least one oily component; an aqueous phase; optionally containing one or more stabilizing agent; and other pharmaceutically acceptable... Agent: Ladas & Parry

20080050435 - Temperature sensitive polymers: The present invention relates to compositions comprising polymers whose solubility characteristics can be changed by incubation and particularly ploy (hydroxyalkyl (meth) acrylamide mono/di-lactate) interpolymers. Another aspect of this invention is the application of such temperature sensitive polymers as release systems of biologically active compounds. The polymers of the present invention... Agent: Morrison & Foerster LLP

20080050436 - Methods and compounds for obliteration of vessels: A minimally invasive method that allows for complete obliteration of the affected vessels without scarring or any of the other undesirable complications of conventional or foam sclerotherapy. More particularly, the present invention relates to a method for using a non-foaming thickener to reduce dilution and diffusion of the sclerosant in... Agent: Jack Chu

20080050437 - Modified release pharmaceutical formulation: A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents hydrogen, hydroxy, methoxy or ethoxy, and n represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable... Agent: Morgan Lewis & Bockius LLP

20080050438 - Dry compositions: A dry composition of the present invention comprises at least one of active ingredients selected from the group consisting of pharmacologically active proteins and pharmacologically active polypeptides and as a stabilizer at least one of hydrophobic stabilizers selected from the group consisting of hydrophobic amino acids, hydrophobic dipeptides and hydrophobic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080050439 - Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans,... Agent: Peters Verny , L.L.P.

20080050442 - Nasal pharmaceutical formulations and methods of using the same: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific... Agent: Alston & Bird LLP

20080050440 - Plant epidemic prevention agent, plant epidemic prevention method, plant epidemic prevention system, plant, and plant cultivation method: The present invention provides a plant epidemic prevention agent that allows for easily and efficiently decomposing and eliminating pathogenic germs that cause plant epidemic and effectively suppressing plant disease caused by the pathogenic germs and making diseased plants recover from the disease without adversely affecting the human body and allows... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080050441 - Process for the preparation of solid sterile active pharmaceutical ingredient: The present invention provides a method of preparing a packed sterile solid active pharmaceutical ingredient, in particular sterile steroids such as a glucocorticosteroid acid.... Agent: Kenyon & Kenyon LLP

20080050445 - Niosome-hydrogel drug delivery: Taught herein is a drug-delivery system that includes encapsulating a therapeutic drug in a nanoparticle vesicle that is then embedded into a hydrogel network. The system allows for enhanced, two-fold control over the release rate of the drug. This technology will be particularly advantageous in treating malignant cancer cells such... Agent: Smith Hopen, Pa

20080050448 - Antimicrobial conjugates: The present invention presents a metallic nanoparticle-ligand-photosensitiser conjugate, a method of making such conjugate, and a method of using such mixture for killing or preventing the growth of microbes.... Agent: Dobrusin & Thennisch PC

20080050443 - Fast release composition including melt granules of a moisture sensitive drug and process for manufacturing thereof: Solid oral dosage forms that include melt granules of a moisture-sensitive therapeutic compound and a hydrophobic melt component. The melt granules better protect the therapeutic compound from hydrolytic degradation. Such solid oral dosage forms also possess immediate-release characteristics rather than that associated with extended-release or controlled-release drug products.... Agent: Novartis Corporate Intellectual Property

20080050446 - Fast release dosage forms for antibiotics: A multiparticulate, pharmaceutical dosage form containing at least one antibiotic which is sparingly wettable with aqueous media or sparingly soluble in aqueous media and a combination of carrageenan and tricalcium phosphate and optionally sucrose ester. Also, an administration system having this dosage form arranged in a drinking straw with at... Agent: Crowell & Moring LLP Intellectual Property Group

20080050444 - Pharmaceutical compositions of ilaparazole: The present invention relates to pharmaceutical compositions comprising solid particles of an active ingredient that have a particle size of from about 0.1 micron to about 100 microns.... Agent: Dykema Gossett PLLC

20080050447 - Residual solvent extraction method and microparticles produced thereby: Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080050449 - Controlled release formulation of tolterodine: The invention encompasses stable multiparticulate pharmaceutical compositions of tolterodine having at least one pharmaceutically acceptable excipient and at least two populations of multiparticulates each population having tolterodine or a salt thereof and the ratio of the populations is from 90:10 to 10:90 by weight, wherein after storage for 1 month... Agent: Kenyon & Kenyon LLP

20080050450 - Active agent formulations, methods of making, and methods of use: Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof,... Agent: Cantor Colburn, LLP

20080050451 - Methods for assessing dehydration and shock, assays and kits for the methods: The present invention is in the medical and consumer arenas. The invention presents the use of a salivary amylase assay to diagnose, quantify, and monitor the hydration status, the onset and progress of shock in an animal that produces salivary amylase, such as a human. The assay tests the saliva... Agent: Wean Khing Wong Attorney At Law

20080050452 - Metal-containing formulations and methods of use: Metal-containing materials, as well as their preparation, formulations, and use are disclosed.... Agent: Fish & Richardson PC

20080050453 - Trace elements: The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium and which comprises a concentration of the metal(s) of at least 60 mg/ml. The solution further comprises at least one compound selected from the group comprising... Agent: Stites & Harbison PLLC

20080050454 - Compositions and methods for nutrition supplementation: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080050455 - Equine gastric ulcer therapy compositions and equine ulcer management method: An equine gastric ulcer therapy composition comprises a pre-packaged, dry feed supplement comprising effective amounts of chamomile tea and an effective amount of slippery elm with effective amounts of apples and a natural sweetener. An alternative composition comprises a pour-able aqueous solution of an effective amount of chamomile tea and... Agent: Blynn L. Shideler The Blk Law Group

20080050456 - Intramammary formulations: The present invention relates to intramammary formulations, as well as methods of treating an intra-mammary infection in a lactating non-human animal and preventing re-infection by internal administration of the formulations. The formulations include a combination of penicillin, aloe vera and Centella asiatica extract.... Agent: Knobbe Martens Olson & Bear LLP

20080050457 - Ginkgo biloba extract and method for producing the same: The invention relates to a Ginkgo biloba extract and to a method for producing the same. The invention especially relates to a Ginkgo extract having an increased content in desired, pharmaceutically effective active ingredients and to a method which uses water as the extractant.... Agent: Schweitzer Cornman Gross & Bondell LLP

20080050459 - Cosmetic lightening preparation: A cosmetic preparation comprises an effective amount of Phyllanthus Embilca fruit extract and at least one oligopeptide such as Oligopeptide-4 and Oligopepticje-5 (pro-Elastin oligopeptide) The cosmetic preparation may further comprise Licorice extract, and Alpha-arbutin. It has surprisingly been found that this cosmetic preparation displays a beneficial synergistic effect for the... Agent: Cohen Pontani Lieberman & Pavane LLP

20080050458 - Lupin total extract consisting of a lupin sugar extract and a lupin peptide extract, method for the production and use thereof: The invention relates to a composition comprising a lupin total extract consisting of a lupin sugar extract, comprising at least 50% galactooligosaccharides by weight, in relation to the weight of dry matter, and a lupin peptide extract. The composition can also contain a chromane derivative or a chromene derivative. The... Agent: Foley And Lardner LLP Suite 500

20080050461 - Nanoparticulate compositions of angiogenesis inhibitors: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20080050460 - Uses of lectin-conotoxin: Provided herein are novel onco-fetal carbohydrate motifs present in adenocarcinoma cells. This novel carbohydrate motif is preferentially recognized by tomato fruit lectin-conotoxin. Also provided are methods for inhibiting proliferation and growth of cancer cells and for treating pathophysiological conditions, e.g., cancer, chronic pain, inflammation and/or a microbial infection, by contacting... Agent: Benjamin Aaron Adler Adler & Associates

20080044349 - Therapeutic and diagnostic applications of perlecan domain i splice variants: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.... Agent: Proteotech, Inc.

20080044351 - Method and procedure to detect oral tissues with high-risk molecular profiles: A diagnostic method for detecting high risk oral tissue which due to chromosome allelic loss and may have developed or will potentially develop into carcinoma in situ and carcinoma by using a staining agent. A set of questionnaire that identifies high-risk individual and high-risk lesions and helps to reduce false... Agent: Xin Ye

20080044350 - Optical imaging contrast agents for imaging lung cancer: The invention provides contrast agents for optical imaging of prostate cancer in patients. The contrast agents may be used in diagnosis of prostate cancer, for follow up of progress in disease development, for follow up of treatment of prostate cancer and for surgical guidance. Further, the invention provides methods for... Agent: Ge Healthcare, Inc.

20080044362 - Cosmetic composition comprising block copolymer templated metal oxide particles: Disclosed are cosmetic compositions containing a metal, a polymer having a non-functional domain and a functional domain having a plurality of functional groups that interact with the metal, and a cosmetically acceptable carrier. Also disclosed are methods and systems for applying the composition to keratinous substrates, whereby aggregates of the... Agent: L'oreal Usa/ Patent Department

20080044369 - Hair care composition: A hair care solution configured to reduce volume and size of the product includes a hydrophilic polymer, and a hair care ingredient encapsulated in the water-absorbent polymer. Accordingly, the encapsulated hair care ingredient is released for use when the hydrophilic polymer is activated with water.... Agent: Rader, Fishman & Grauer PLLC

20080044371 - Taste-masked composition of cationic exchange resin: The present invention provides a taste-masked composition containing an active compound. The composition is taste-masked by employing a loaded polymeric matrix which is produced by incorporating or complexing the active compound on a polymeric matrix having ionic functional groups and removing unbound active compounds from the polymeric matrix.... Agent: Novartis Corporate Intellectual Property

20080044376 - Cytokine design: The present invention relates to novel methods for the design of proteins, in particular, cytokines. These methods allow the stabilisation of such cytokines, as well as modification of their selectivity/specificity for their cognate receptors. The invention also relates to various modified proteins that have been designed by the methods of... Agent: Woodcock Washburn LLP

20080044379 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080044380 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080044377 - Poxvirus vector encoding retrovirus (eg hiv) and cytokine: In one embodiment, there is provided a method for treatment or prophylaxis of one or more symptoms of a retrovirus infection such as HIV infection, comprising the administration of poxvirus vector encoding a retrovirus antigen and a cytokine, or a functional homolog, derivative part or analog thereof, in conjunction with... Agent: Scully, Scott, Murphy & Presser, P.C.

20080044392 - Isolation of stem cell-like cells and use thereof: The present invention relates to isolated stem cell-like cells and a method of isolation. The invention also relates to a media composition for producing primary cell cultures comprising predominantly tissue-specific progenitor cells or stem cell-like cells. In particular, the present invention relates to an isolated mesenchymal connective tissue-derived stem cell.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080044396 - Method of raising livestock: The present invention provides a method of raising livestock, which can improve an efficiency of propagating or rearing without using a drug such as an antibiotic or a disinfectant. The method uses a lactic acid bacterium (such as Enterococcus faecium or Lactobacillus fermentum) proliferated and cultured in a medium containing... Agent: Smith, Gambrell & Russell

20080044397 - Compositions to reduce or prevent skin cancer: Compositions of human proteins, methods and regimens for reducing the occurrence and growth of skin cancer, including melanoma, are provided. The methods include steps of administering topically on the skin tumor or a skin cancer-free area of compositions containing therapeutically effective amounts of human alkaline phosphatase, transferrin and α1-antitrypsin. In... Agent: Faegre & Benson LLP Patent Docketing

20080044348 - Tetanus toxin fragment c based imaging agents and methods, and confocal microscopy dataset processes: Methods for purifying Tetanus Toxin Fragment C comprising obtaining a supernatant comprising soluble Tetanus Toxin Fragment C and purifying Tetanus Toxin Fragment C under native conditions to obtain a substantially purified Tetanus Toxin Fragment C. Imaging agents comprising a Tetanus Toxin Fragment C and a reporter, and methods thereof. Methods... Agent: Baker Botts, LLP

20080044352 - Compositions and methods for lipoprotein uptake assays: Provided herein are compositions and methods for lipoprotein uptake assay. These compositions and methods may be used for lipoprotein uptake assays, including high-throughput assays. The disclosed compositions and method may further be used to characterize the activity agents that inhibit or stimulate lipoprotein uptake.... Agent: General Electric Company Global Research

20080044356 - Assemblies of oligomeric amyloid beta protein and uses thereof: The present invention provides assemblies of oligomeric amyloid beta protein and uses thereof.... Agent: Mueting, Raasch & Gebhardt, P.A.

20080044353 - Combination therapy for weight management: Compositions and methods are provided for weight management. The compositions generally comprise a MCHR antagonist, either in combination with a CB1 antagonist or formulated for coadministration with a CB1 antagonist. Certain methods involve coadministering a MCHR antagonist and a CB1 antagonist to a patient.... Agent: Cantor Colburn, LLP

20080044354 - Compounds containing a n-heteroaryl moiety linked to fused ring moieties for the inhibition of nad(p)h oxidases and platelet activation: The invention relates to compounds containing a N-heteroaryl moiety, which is linked via oxygen, sulfur or nitrogen, or via a methylene bridge and oxygen, sulfur or nitrogen to a fused ring moiety, in particular to the 1,2,3-triazolo[4,5d]pyrimidine-7-yl radical. The invention also relates to a process for the preparation of said... Agent: Thelen Reid Brown Raysman & Steiner LLP

20080044357 - Methods and systems for high throughput research of ionic liquids: The present invention provides a method and a system for processing a plurality of ILs, wherein the processing comprises one or more selected from the group of synthesis, separation, detection, purification, determination and so on, and the methods and systems for processing applies high throughput technique. By using the high... Agent: Perkins Coie LLP

20080044355 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Jonathan P. O'brien

20080044358 - Methods for lymph system imaging: Methods and contrast agents for imaging the lymph system are provided. The methods allow the diagnosis and staging of diseases of the lymph system, such as cancer and infections.... Agent: Fish & Richardson P.C.

20080044359 - Cell permeable probe: A cell permeable probe is disclosed. The cell permeable probe includes a cell membrane translocating element, which facilitates transport of the probe into the intracellular component of a cell. The cell permeable probe may also include a plurality of binding moieties for a disease specific marker and a contrast agent.... Agent: Mcdonald Hopkins LLC Suite 2100

20080044360 - Methods of collagen imaging: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.... Agent: Fish & Richardson P.C.

20080044361 - Hfa suspension formulations containing an anticholinergic: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080044363 - Therapeutic dental composition: A solid or semi-solid oral therapeutic dental composition comprising a therapeutic agent dispersed in a water-insoluble or water-resistant carrier. The dental composition may be in the form of a crayon or dispensed from a delivery device such as a pen or the like.... Agent: Discus Dental Impressions, Inc.

20080044364 - Flavonoid complexes: where R1 to R10 may be identical or different and are selected from H, OR11, straight-chain or branched C1- to C20-alkyl groups or hydroxyalkyl groups, straight-chain or branched C3- to C20-alkenyl groups and/or C3- to C12-cycloalkenyl groups, where the rings may each also be bridged by —(CH2)n— groups, where n=1... Agent: Millen, White, Zelano & Branigan, P.C.

20080044365 - Concave or annular particles of silicone materials for increasing the sun protection factor of aqueous photoprotective compositions comprising same: Sunscreen compositions having increased SPF contain at least one aqueous phase, at least one organic UV screening agent and/or at least one inorganic UV screening agent, notably at least one wetting agent, and an effective SPF-increasing amount of concave or annular particles of a silicone material, formulated into a physiologically... Agent: Buchanan, Ingersoll & Rooney PC

20080044366 - Compositions for application to the skin, to the lips, to the nails, and/or to hair: The present disclosure relates to compositions comprising particles of at least one composite pigment, the particles comprising an inorganic core which is at least partially coated with at least one organic coloring substance, wherein the composition has a covering power ranging from 1 to 25, and wherein the at least... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080044367 - Cosmetic compositions with film forming polymer: A cosmetic composition for coloring, conditioning, or beautifying keratinous surfaces comprising at least one film forming polymer which comprises vinyl ester monomers.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20080044368 - Durable hair treatment composition: Topical compositions for treating hair are presented. The compositions comprise functionalized silicones having defined physicochemical properties that exhibit superior conditioning duability on hair than previously known silicone based conditioners, especially where the hair has been previously damaged through chemical treatments, such as occurs during permanent dyeing, bleaching and permanent waving.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080044370 - Composition for scalp and hair of scalp: An object of the present invention is to provide scalp and hair of scalp composition which realizes hair growing, hair growth or the like by arranging the scalp environment without inhibiting the function of sebaceous membrane and dark cell (superficial type cell) of scalp. To achieve the object, the present... Agent: Oliff & Berridge, PLC

20080044372 - Transfer-resistant makeup removing compositions: The invention relates to a cleansing composition suitable for topical application to human skin, more particularly to an oil-based cleansing composition containing a silicone elastomer gelling agent for removal of make-up from the skin.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080044373 - Cosmetic composition for the lips, combining a phosphate surfactant and a silicone polymer: The present invention relates to a cosmetic composition for the lips, comprising, in a physiologically acceptable medium, at least: one phosphate surfactant, and one silicone polymer comprising at least one unit comprising: (1) polyorganosiloxanes comprising at least two groups capable of establishing hydrogen interactions, these two groups being in the... Agent: Oliff & Berridge, PLC

20080044374 - Polymer cement for percutaneous vertebroplasty and methods of using and making same: The invention provides a fluid cement for medical use for bone reconstruction, in particular for filling the vertebral body, and a binary composition which is intended for the preparation of such a cement. The invention also provides a device for conditioning the binary composition, and a method of preparing a... Agent:

20080044375 - Compositions and methods for attracting noctuid moths: The invention provides compositions for attracting stink bugs, which include at least one pheromone and at least one synergist The synergist is a naturally-occurring phytochemical compound. The pheromone is preferably methyl (2E,4Z)-decadienoate, ethyl (2E,4Z)-decadienoate, methyl (2Z,4E)-decadienoate, or methyl (2E,4E)-decadienoate and the synergist is preferably geraniol. The invention also provides traps... Agent: Thelen Reid Brown Raysman & Steiner LLP

20080044378 - Methods and compositions for protein production using adenoviral vectors: The present invention provides methods and compositions for recombinant protein production through replication-defective adenoviral vector infection of non-trans-complementation cell lines. Thus, this invention describes methods of heterologous protein production without an accompanied production of adenoviral vectors.... Agent: Fulbright & Jaworski L.L.P.

20080044381 - Stable liquid interferon formulations: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080044382 - Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds: Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment. Monitoring for the JC virus... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080044383 - Compositions and methods for modifying cell surface glycans: Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080044385 - Novel modified galectin 8 proteins and use thereof: Recombinant galectin 8 (rGal 8), produced in host Escherichia coli, exerts hemagglutinating activity, neutrophil adhesion inducing activity, integrin αM-binding activity, proMMP-9 binding activity, active form MMP-9 production promoting activity, superoxide production promoting activity, apoptosis inducing activity for a particular cell, suppressive or inhibitory activity against the metastasis/invasion of tumor cells,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080044386 - Protamine-adenoviral vector complexes and methods of use: Embodiments of the invention include methods and compositions including viral composition that have high transduction efficiencies in vivo, in vitro and ex vivo. The viral composition include a viral vector and a protamine molecule, wherein the viral vector includes a polynucleotide encoding a tumor suppressor gene. The methods of the... Agent: Fulbright & Jaworski L.L.P.

20080044384 - Recombinant human cytomegalovirus and vaccines comprising heterologous antigens: The present invention relates to recombinant HCMV (human cytomegalovirus) expressing a pp65 polypeptide or fragment thereof fused to a heterologous or non-native polypeptide, in particular immunogenic and/or antigenic polypeptides. In particular, the heterologous gene products include antigenic or immunogenic polypeptides from a variety of pathogens, cellular genes, tumor antigens, and... Agent: Johnathan Klein-evans

20080044391 - Different dendritic cell subsets: It is intended to provide expired dendritic cells having characteristics of the following (E1) to (E3): (E1) not shifting into a mature type due to an action of a natural immune stimulant or a permanent immune potentiator; (E2) having the same shape as immature DC; and (E3) expressing IL-10. It... Agent: Knobbe Martens Olson & Bear LLP

20080044395 - In vitro method for isolating, proliferating and differentiating germ-line stem cells: The present invention discloses methods for isolating, proliferating and differentiating germ-line stem cell in vitro. More specifically, the present invention discloses a method for the in vitro isolation and proliferation of mammalian germ-line stem cells, characterized in culturing cells isolated from mammalian testis in an embryonic stem cell culture medium,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080044394 - Methods for genetic modification of hematopietic progenitor cells and uses of the modified cells: Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene... Agent: Cooper & Dunham, LLP

20080044393 - Retinal dystrophin transgene and methods of use thereof: Duchenne muscular dystrophy (DMD) is a progressive muscle disease that is caused by severe defects in the dystrophin gene and results in the patient's death by the third decade. The present invention utilizes the Double Mutant mice (DM) as an appropriate human model for DMD as these mice are deficient... Agent: Erickson & Kleypas, L.L.C.

20080044387 - Artificial niches for enhancement of regenerative capacity of stem cells in aged and pathological environments: Artificial niches which provide growth, differentiation, and/or anti-aging environments for stem cells and progenitor cells are described.... Agent: Morgan, Lewis & Bockius, LLP

20080044388 - Method for production of arachidonic acid: The present invention relates to a process for producing arachidonic acid. In one embodiment, Mortierella sect. schmuckeri microorganisms are cultured in fermentation medium, preferably containing a component of a complex nitrogen source. Further disclosed is a food product which includes Mortierella sect. schmuckeri microorganisms or lipid isolated from such microorganisms... Agent: Sheridan Ross P.C.

20080044389 - Method for production of arachidonic acid: The present invention relates to a process for producing arachidonic acid. In one embodiment, Mortierella sect. schmuckeri microorganisms are cultured in fermentation medium, preferably containing a component of a complex nitrogen source. Further disclosed is a food product which includes Mortierella sect. schmuckeri microorganisms or lipid isolated from such microorganisms... Agent: Sheridan Ross P.C.

20080044390 - Methods and compositions for the treatment of neurodegenerative disorders: The present invention features compositions, kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease.... Agent: Clark & Elbing LLP

20080044398 - Soluble composition having enzymatic activity and improved stability: A dry, powdered enzyme is dispersed in a dry, powdered maltodextrin carrier by dry mixing to provide a soluble composition having enzymatic activity and improved stability. The composition provides fibrinolytic activity when the enzyme is a fibrinolytic enzyme, such as nattokinase, and the fibrinolytic activity is added to supplement foods... Agent: Vesta Ingredients, Inc.

20080044399 - Vitamin e supplementation for reducing cardiovascular events in individuals with dm and the hp 2-2 genotype: This invention relates to methods and compositions of determining the benefit of therapy using vitamin-E for the treatment of cardiovascular events in individuals with diabetes melitus based on their Haptoglobin phenotype and the treatment of the cardiovascular events using vitamin-E based on the haptoglobin phenotype.... Agent: Pearl Cohen Zedek Latzer, LLP

20080044401 - Drug therapy for celiac sprue: Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.... Agent: Bozicevic, Field & Francis LLP

20080044400 - Targeted enzyme prodrug therapy: The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes.... Agent: Genencor International, Inc. Attention: Legal Department

20080044402 - Use of fermented wheat-germ in the feeding and veterinary practice: This invention relates to new uses of fermented wheat-germ extract namely for purposes of animal feeding and veterinary therapy. The subject matters of this invention are also the fodders, nutriments, premixes and veterinary preparations containing fermented wheat-germ extract.... Agent: Birch Stewart Kolasch & Birch

20080044404 - Annexin v for preventing atherothrombosis and plaque rupture: Atherosclerosis can be viewed as a response to injury and it is not atherosclerosis per se that is serious but instead factors leading to rupture of atherosclerotic plaques. In the present invention we have identified such factors. A decreased binding of Annexing V to the endothelium was seen in patients... Agent: Fulbright & Jaworski L.L.P.

20080044403 - Immune markers used for diagnosis and therapy in connection with transplant reactions: The invention relates to immune markers for detecting inflammations, immune reactions, and particularly transplant tolerance or transplant reactions, a method for detecting transplant reactions or tolerance, and the use of immune markers for medical prophylaxis, clinical monitoring of progress, transplant follow-up treatment, clinical diagnosis and/or therapy in connection with cell... Agent: Wood, Herron & Evans, LLP

20080044407 - Mage-a3/hpv 16 peptide vaccines for head and neck cancer: The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the... Agent: Merchant & Gould PC

20080044406 - Neuroactive fragments of app: The application provides novel neuroactive fragments of human amyloid precursor protein (APP). The fragments include sequence from the Aβ region of APP but also extend upstream. The fragments are soluble in aqueous solution most bands are about 10 kDa and above and do not correspond with the expected molecular weight... Agent: Townsend And Townsend And Crew, LLP

20080044405 - Noble metal complex-mediated immunosuppression: Certain noble metal complexes are able to strip peptides from class II MHC proteins, resulting in class II MHC peptides in a peptide-empty conformation that do not support T-cell activation. Methods for identifying additional compounds are provided. Also provided are methods for use of this class of compounds to inhibit... Agent: Wolf Greenfield & Sacks, P.C.

20080044408 - Cytotoxicity mediation of cells evidencing surface expression of cd63: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.A.

20080044411 - Human glp-1 mimetibodies, compositions, methods and uses: The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of... Agent: Philip S. Johnson Johnson & Johnson

20080044409 - Inflammatory mediator antagonists: The present invention relates to methods of reducing cartilage degradation in a patient comprising administering to a patient in need thereof an effective amount of an antibody antagonist to the mature form of OSM.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080044410 - Neutralizing antibodies against gdf-8 and uses therefor: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080044412 - Single-domain antibody strengthening fusion protein vh-ldp-ae: The present invention relates to a novel antibody-based targeting drug—a single domain antibody energized fusion protein VH-LDP-AE with potent cancer cell killing activity, anti-angiogenic activity, and anti-cancer therapeutic efficacy, to a method for producing the same, and use thereof in manufacture of an anti-tumor medicament.... Agent: Ladas & Parry

20080044413 - Epha2 bite molecules and uses thereof: The present invention relates to bispecific single chain antibodies comprising a first binding domain that immunospecifically binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTEs.” The present invention further relates... Agent: Jones Day

20080044414 - Il-1beta binding antibodies and fragments thereof: An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding... Agent: Mcandrews Held & Malloy, Ltd

20080044415 - Hepatocyte growth factor receptor antagonists and uses thereof: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions,... Agent: Genentech, Inc.

20080044417 - Humanized fc.gamma.riib-specific antibodies and methods of use thereof: The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc... Agent: King & Spalding

20080044416 - Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described.... Agent: Fulbright & Jaworski L.L.P.

20080044418 - Tumor antigens and uses thereof: The invention features tumor antigens; tumor antigen-encoding nucleic acids; antibodies specific for tumor antigens and methods of using the antibodies; methods of identifying tumor antigens and the nucleic acids that encode them; methods of monitoring or diagnosing tumors in patients; methods of testing patients for the increased likelihood of developing... Agent: Bromberg & Sunstein LLP

20080044419 - Treatment of t cell mediated diseases by inhibition of fgfr3: The present invention provides a method of preventing and treating a T cell mediated disease, including inflammatory autoimmune diseases and in particular rheumatoid arthritis, by administering to an individual in need thereof at least one FGFR 3 inhibitor including a molecule comprising the antigen-binding portion of an antibody having a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080044424 - Antagonists of protease activated receptor-1 (par1): The present invention provides antibodies or antigen-binding molecules that specifically recognize and antagonize human PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.... Agent: Towmsend & Townsed & Crew LLP

20080044420 - Anti-il-13 antibodies, compositions, methods and uses: The present invention relates to at least one novel anti-IL-13 antibody, including isolated nucleic acids that encode at least one anti-IL-13 antibody, IL-13, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.... Agent: Philip S. Johnson Johnson & Johnson

20080044422 - Cngh0010 specific polynucleotides, polypeptides, antibodies, compositions, methods and uses: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic... Agent: Philip S. Johnson Johnson & Johnson

20080044423 - Compounds: Binding members, especially antibody molecules, for interleukin 17 (IL-17). The binding members are useful for the treatment of disorders associated with interleukin 17 such as rheumatoid arthritis.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080044421 - Methods of using death receptor ligands and cd20 antibodies: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies... Agent: Genentech, Inc.

20080044425 - Polypeptides having phospholipase a2 activity: The present invention relates to a novel phospholipase A2 polypeptide, DNA encoding the polypeptide, a vector comprising the DNA, a transformant transformed with the vector, and a process for producing the phospholipase A2 polypeptide. The present invention also relates to a method of utilizing the polypeptide, e.g., a method of... Agent: Fitzpatrick Cella Harper & Scinto

20080044426 - Novel atypical pneumonia-causing virus: The invention relates to the field of virology. The invention provides a new isolated essentially mammalian positive-sense single stranded RNA virus (EMCR-CoV) within the group of coronaviuses and components thereof.... Agent: Hoffmann & Baron, LLP

20080044427 - Plant virus: The invention relates to the field of virology. The invention provides an isolated plant virus (ToTV) named Tomato torrado virus (ToTV), and components thereof. The invention further relates to methods of producing a ToTV-resistant plant comprising the steps of identifying a ToTV-resistant donor plant, crossing said ToTV-resistant donor plant with... Agent: Banner & Witcoff, Ltd.

20080044430 - Agent for stimulating the production of a blood coagulation factor viii: The inventive agent comprises polyclongal immunoglobulins of IgG class whose molecular mass is equal to 150 kD and which are obtainable in the form of a humoral immune response to an endothelial and mesenchymal stem cells complex.... Agent: Houston Eliseeva

20080044429 - Fc.gamma.riib-specific antibodies and methods of use thereof: The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent... Agent: King & Spalding

20080044428 - Glycosylphosphatidylinositol glycan signalling via integrins functioning as glycan specific receptors: The present invention relates generally to a method of modulating integrin-mediated cellular activity and to agents useful for same. More particularly, the present invention contemplates a method of modulating ab integrin-mediated cellular activity by modulating GPI-related signalling. The method of the present invention is useful, inter alia, in the treatment... Agent: Scully Scott Murphy & Presser, PC

20080044432 - Mammalian receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080044431 - Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms: A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.... Agent: Burr & Brown

20080044433 - Epitopes of hepatitis c virus: The invention provides compositions containing HCV epitopes, which are recognized by cytotoxic T lymphocytes. Such polypeptides are used in prophylactic vaccines, immunotherapies, and assays to monitor the progress or success of immune interventions. The compositions are optimized to elicit an immune response in a genetically-diverse population of individuals.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080044434 - Coated material and process for producing the coated material: A coated material and a process for producing the coated material which includes providing a coating agent comprising yeast cell wall fractions, as a primary constituent, consisting of cell residue of yeast which has been treated with enzymes, optionally subsequently with acidic solution, and water to remove internal soluble cell... Agent: Venable LLP

20080044435 - Tat-based tolerogen compositions and methods of making and using same: A Tat-based tolerogen composition comprising at least one immunogenic antigen couplet to at least one human immunodeficiency virus (IIIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080044436 - Method for screening and compositions for treating cancers: The invention relates to compositions and methods for treating proliferative pathologies, in particular cancers. The invention is based on the identification of particular properties of TReP-132 in the control of the cell cycle and in the control of cell proliferation. Said protein behaves as a tumor suppressor and is therefore... Agent: Nixon & Vanderhye, PC

20080044437 - Encapsidation system for production of recombinant virus-like particles: The present invention relates to methods and compositions for manufacturing virus-like particles (VLPs), suitable for use as immunogens and as research tools. The VLPs of the present invention provide a sale alternative to the use of pathogenic viruses for clinical and laboratory applications.... Agent: Medlen&carroll

20080044438 - Yeast cell particles as oral delivery vehicles for antigens: Provided herein are yeast cell particles (YCPs) comprising an antigen for use, e.g., as an oral, inhalation, mucosal or parenteral delivery vehicle for the antigen. A YCP may be obtained from a yeast cell by a process that removes at least some of the mannan from the outer cell wall... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080044439 - Compositions and methods for preventing and treating skin and hair conditions: The present invention discloses compositions and methods for the prevention and treatment of skin and hair diseases, such as, for example, alopecia, psoriasis, and keloids. The present invention also relates to compositions and methods for altering skin coloration. The present invention also relates to methods for enhancing the effect of... Agent: Wilson Sonsini Goodrich & Rosati

20080044440 - Vaccine formulated for administration to mucosa of the lungs: There is disclosed vaccines formulated for administration to the mucosa of the lungs of a mammal, and the use thereof in methods for prophylaxis or treatment of an infection by at least one pathogenic microorganism. The vaccines comprise a cellular fraction of the microorganism that is essentially free of particulate... Agent: Pearne & Gordon LLP

20080044441 - Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer: This invention relates to compositions comprising multi-haptenized tumor cells and extracts thereof, methods for preparing the compositions, vaccines comprising such multi-haptenized tumor cells, and methods for treating cancer with such vaccines. In a specific embodiment, melanoma and ovarian adenocarcinoma cells are multi-haptenized, wherein the tumor cells are differentially haptenized either... Agent: Morgan, Lewis & Bockius LLP

20080044442 - Container for an inhalation anesthetic: The specification and drawings describe and show one preferred embodiment or a small number of preferred embodiments of the present invention in the form of a container constructed from or lined with a material comprising a copolymer of acrylonitrile, methyl acrylate, and butadiene, said container defining an interior space constructed... Agent: Norris, Mclaughlin & Marcus, Pa

20080044445 - Cosmetic composition and carrier: A cosmetic polymer includes a water absorbent polymer, and a cosmetic ingredient encapsulated in the water absorbent polymer. Encapsulating a cosmetic ingredient in an absorbent polymer allows for systematic release of the cosmetic ingredient, thereby reducing the negative effects of preservatives found in many cosmetic ingredients.... Agent: Rader, Fishman & Grauer PLLC

20080044444 - Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof: The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected... Agent: Wilmerhale/boston

20080044443 - Method of applying makeup by means of a magnetic composition including at least one coloring agent producing a color by absorbing at least a fraction of the visible spectrum: The present invention relates to a method of applying makeup to keratinous substances, in particular such as the skin, the lips, the nails, or hair, the method comprising the following steps: depositing at least one cosmetic composition on keratinous substances, the cosmetic composition comprising: at least one body that presents... Agent: Oliff & Berridge, PLC

20080044446 - Compositions and methods for attracting noctuid moths: The invention provides compositions for attracting noctuid moths, which include at least one pheromone and at least one synergist. The synergist is a naturally-occurring phytochemical compound. The synergist is preferably β-caryophyllene, iso-caryophyllene, α-humulene, or combinations thereof. The invention also provides traps containing the composition for attracting noctuid moths, and methods... Agent: Thelen Reid Brown Raysman & Steiner LLP

20080044447 - Bone semi-permeable device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20080044448 - Bone semi-permeable device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20080044449 - Medical implant sheets useful for tissue regeneration: Described is a medical device in the form of a thin sheet having granules of a calcium-containing, osteoconductive material interconnected by a thin web of polymeric material. The device includes a first face and a second face, wherein at least the first face is populated with proturbances presenting exposed regions... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080044451 - Biological surfaces: A base body contains a substrate that is at least partially coated with a carbon-containing layer. The carbon-containing layer is at least partially functionalized with a molecule that is bound directly or via at least one linker or functional group to the carbon-containing layer. The base body, which has a... Agent: Lerner Greenberg Stemer LLP

20080044452 - Drug delivery system for treatment of transitional cell carcinoma: A system for treating tissue carcinomas and benign inflammatory conditions of the urinary tract includes a flowable medium containing a bioactive agent and a thermogelling aqueous polymer solution. The thermogelling aqueous polymer solution maintains the bioactive agent within the urinary tract for a therapeutically optimal period of time. One embodiment... Agent: Cardinal Law Group

20080044450 - Sustained release composition: A sustained release apparatus including at least one sustained release mini-implant or pellet; the or each mini-implant or pellet including: a sustained release support material; and a pharmaceutical composition including a Luteinising Hormone Releasing Hormone (HLRH) agonist and/or antagonist component the size and/or number and/or payload of mini-implant(s) or pellet(s)... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080044453 - Therapeutic agent for treatment of autoimmune diseases: In the present invention, there are disclosed a therapeutic agent for the treatment of a disease in which the suppression of Thl cytokine production is therapeutically effective and/or a disease in which the suppression of autoantibody production is therapeutically effective, a therapeutic agent for the eradicative treatment of these diseases,... Agent: Foley And Lardner LLP Suite 500

20080044455 - Tonsillitus treatment: A therapeutic agent and methodology for treatment of tonsillitis and tonsil, throat and mouth infection is provided as a combination of Lactic Acid and a delivery vehicle, such as an ingestible liquid. The agent is ingested by an individual with a spacing between applications thereof, such that recurrence of tonsil... Agent: Patterson & Sheridan, L.L.P.

20080044454 - Uniform films for rapid dissolve dosage form incorporating taste-masking compositions: The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast... Agent: Hoffmann & Baron, LLP

20080044456 - Cellulose membrane drying process: A method of membrane drying of bacterial cellulose, characterized by the fact that the membrane is stuck to a device and under tension, for acquirement of a dry pellicle with plain, flat and flexible structure.... Agent: Mccormick, Paulding & Huber LLP

20080044458 - Anticrobial polymeric film: An anti-microbial polymeric film comprising a polymeric substrate layer and an inorganic anti-microbial compound of formula (I): AgaHbAcM2(PO4)3.nH2O wherein: A is at least one ion selected from an alkali or alkaline earth metal ion; M is a tetravalent metal ion; a is in the range 0.4 to 0.5; b and... Agent: Ratnerprestia

20080044457 - Pharmaceutical composition comprising temozolomide ester: The present invention discloses general formula I of Temozolomide-8-carboxylate compounds, the process for preparation, pharmaceutical compositions comprising the compounds and the use of the compounds and pharmaceutical compositions for the manufacture of an antitumor medicament. The said pharmaceutical composition comprises one or more general formula I Temozolomide-8-carboxylate compounds as active... Agent: Greenberg & Lieberman, LLC

20080044459 - Enzymatic debridement therapy for abnormal cell proliferation: Compositions and methods are provided to destroy internal cancerous lesions selectively by the administration of a combination of a debridement protease enzyme and a denaturant of cell structural proteins and or cell adhesion proteins.... Agent: King & Spalding LLP

20080044460 - Rechargeable dermal patch: A dermal patch includes a reservoir layer made of a polymer gel provided for receiving a liquid containing an active substance and having a first face to be applied onto the skin of a user in order to diffuse the active substance to the skin. The patch further includes a... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20080044462 - Stabilized transdermal bupropion preparations: Pharmaceutical compositions for transdermal administration containing a fatty acid salt, a dicarboxylic acid salt, an alkyl sulfonic acid salt, an aryl sulfonic acid salt, or an alkyl aryl sulfonic acid salt of an unstable active agent, such as bupropion free base or a derivative of burpropion free base, such as... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080044461 - Transdermal methods and systems for treating alzheimer's disease: Transdermal delivery systems for delivery of Alzheimer's pharmaceuticals, particularly donepezil, over one to seven days are disclosed which deliver the free-base form of the Alzheimer's pharmaceutical at a skin permeation rate such that blood levels of the Alzheimer's pharmaceuticals are comparable to the approved oral dosage forms.... Agent: Alexander R. Pagano, Esq.

20080044463 - Bradykinin b2 receptor antagonist peptide from amphibian skin: A bradykinin B2-receptor antagonist peptide, kinestatin, isolated from toad (Bombina maxima) defensive skin secretion, and analogs thereof, is disclosed. The structure of kinestatin is pGlu-Leu/Ile-Pro-Gly-Leu/Ile-Gly-Pro-Leu/Ile-Arg-NH2. Also disclosed are kinestatin analogs, prodrugs including the peptides, fusion peptides and multimeric peptides including the peptide sequences, pharmaceutical compositions including kinestatin and analogs thereof,... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080044464 - Liposome loading with metal ions: This invention relates to encapsulation of drugs and other agents into liposomes.... Agent: Morrison & Foerster LLP

20080044465 - Therapy for cellular accumulation in chronic inflammatory diseases: The present invention provides a novel method for the treatment of cellular accumulation in chronic inflammatory diseases such as rheumatoid arthritis. The method includes gene delivery and gene expression that is capable of enhancing apoptosis of accumulating cells and those cells which recruit accumulating cells. Also provided are diagnostic methods... Agent: Dla Piper US LLP

20080044466 - Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment: The present invention relates to optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical... Agent: Ladas & Parry

20080044467 - Formulation and process for drug loaded cores: The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core.... Agent: Hedman & Costigan P.C.

20080044470 - Pharmaceutical composition with controlled acitve ingredient release for active ingredients with good solubility in water: b) a coating which envelops the core and which comprises a polymer content of (meth)acrylate copolymers which have not more than 15% by weight of cationic or anionic groups, and which comprises at least 60% by weight of a (meth)acrylate copolymer which is composed of free-radically polymerized units of 93... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080044468 - Processes for the preparation of oral dosage formulations of modafinil: The present invention relates to a method for the preparation of bioavailable dosage form of modafinil.... Agent: Ranbaxy Inc.

20080044469 - Rapidly dispersible, fine-particle film-coating composition which is in powder form, is not prone to segregation and is baased on polyvinyl alcohol-polyether graft copolymers characterized by particular physical stability and low asperity: A rapidly dispersible, fine-particle film-coating composition which is in powder form and is not prone to segregation for coating pharmaceutical dosage forms, consisting of a) 40-90% by weight of a polyvinyl alcohol-polyether graft copolymer (component A), b) 1-20% by weight of a polyvinylpyrrolidone or of a vinylpyrrolidone-vinyl acetate-copolymer with a... Agent: Connolly Bove Lodge & Hutz LLP

20080044471 - Neurotherapeutic compositions: Novel neuroprotectant compositions and methods are described. β-Lactamase inhibitors are used to prevent or reduce loss of neuronal cells and neuronal cell function in patients afflicted with or susceptible to disease states or conditions known to result in or cause neuronal tissue insult.... Agent: Barnes & Thornburg LLP

20080044473 - Methods of reducing nervous system glial scar formation using cyclosporine components: This invention relates to methods of treating mammals at risk or affected by central nervous glial scarring by administering a cyclosporine component. Among the conditions treated are, but not limited to, epidural scarring, meningeal fibrosis, arachnoiditis, nerve root tethering, brain and spinal cord injury, as well as peripheral nerve, tendon... Agent: Milan Radojicic

20080044472 - Photoresponsive hydrogels: Disclosed are photoresponsive hydrogels. The compositions disclosed herein can be prepared by polymerizing a hydrogel precursor and a spiropyran. The properties of the disclosed compositions can be changed by exposure to light, pH, and temperature. Methods of using the disclosed compositions to deliver pharmaceutical actives are also disclosed.... Agent: Needle & Rosenberg, P.C.

20080044474 - Dispersions of nanoureas comprising biologically active compounds: The present invention relates to dispersions of nanoureas comprising biologically active compounds, a process for their preparation, and their use.... Agent: Bayer Material Science LLC

20080044475 - Absorption and bioavailability of carotenoids, formulations and applications: A process for obtaining a microscopic physical state of xanthophylls or oxycarotenoids derivatives forms such as diacetates or dipropionates derivatives, which are readily incorporated in the digestive system as micelles providing an improved bioavailability, as compared to the bioavailability of carotenoids that are ingested in diverse preparations that contain microscopic... Agent: Abelman, Frayne & Schwab

20080044476 - Peripherally administered viscous formulations: Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10... Agent: Allergan, Inc.

20080044479 - Antimicrobial sanitizing formulations with skin protection properties: The present invention is directed toward antimicrobial sanitizing formulations in the form of a medicated polymer/emulsion based product and the method by which it is produced. The products may be used as a topical antimicrobial and skin cleanser, which contain at least one antimicrobial agent in a base which forms... Agent: Mchale & Slavin, P.A.

20080044477 - Adsorbent for an oral administration, and agent for treating or preventing renal or liver disease: An adsorbent for an oral administration, comprising a spherical activated carbon wherein an average particle diameter is 50 to 200 μm, a specific surface area determined by a BET method is 700 m2/g or more, and a bulk density is less than 0.54 g/mL is disclosed. The adsorbent for an... Agent: Reed Smith LLP

20080044478 - Preparation of injectable suspensions having improved injectability: Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080044480 - Technical process and plant for the production of coacervate capsules: The invention relates to a process and the corresponding plant for the production of micro-capsules on an industrial scale for the application in foodstuffs technology, chemical and/or pharmaceutical industry, and in medicine. Said capsules are produced by the so-called coacervate method. They may contain non-living ingredients, e.g. solids, liquids, etc.... Agent: Bodner & O'rourke, LLP

20080044481 - Microparticles for oral delivery: The invention provides microbeads containing oil-associated biologically active compounds and methods for their manufacture and use. The microbeads consist of a soluble complex of non-digestible polymer and emulsifier with oil-associated biologically active compounds embedded in a matrix of digestible polymer. The disclosed microbead complex protects the biologically active compounds, such... Agent: Duane Morris, LLPIPDepartment

20080044482 - Orally administrable opioid formulations having extended duration of effect: Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in... Agent: Jones Day

20080044483 - Metal oxide composition: A composition comprises a non-ionic surfactant and hydrophobic particles of metal oxide having the mean length of the primary particles in the range from 50 to 90 nm, the mean width of the primary particles in the range from 5 to 20 nm, and the median volume particle diameter of... Agent: Jones Day

20080044484 - Use of polymeric nanoparticles for vaccine delivery: The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration... Agent: Dla Piper US LLP

20080044485 - Preparation of injectable suspensions having improved injectability: Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080044486 - Controlled food effect composition: The invention provides a pharmaceutical composition for oral administration comprising an active substance having a food effect, in combination with a lipid material comprising membrane lipids, which is characterised in showing a reduced food effect. The invention also refers to the use of a lipid material comprising membrane lipids for... Agent: Dickstein Shapiro LLP

20080044487 - Anti-inflammatory properties of marine lipid compositions: Novel marine lipid compositions comprising triglycerides and omega-3 rich phospholipids are described. The compositions are characterized by providing highly bioavailable omega-3, increased tissue incorporation of omega-3 and reduced concentration of pro-inflammatory cytokines.... Agent: Casimir Jones, S.c.

20080044488 - Nano glass powder and use thereof, in particular multicomponent glass powder with a mean particle size of less than 1 µm: A glass powder or a glass-ceramic powder is provided that includes multicomponent glasses with at least three elements, where the glass powder or a glass-ceramic powder has a mean particle size of less than 1 μm. In some embodiments, the mean particle size is less than 0.1 μm, while in... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080044489 - Low dose colonic cleansing system: A method of colonic cleansing that includes administering orally a first dose and a second dose of a liquid osmotic colonic evacuant composition. The second dose includes an amount of the liquid osmotic colonic evacuant composition that is 55% to 95% of the amount of the first dose.... Agent: Evan Law Group LLC

20080044490 - Sterile low bicarbonate dialysis concentrate solutions: The present invention relates to a sterile calcium-free low bicarbonate dialysis concentrate composition for use in conjunction with regional citrate anti-coagulation in the context of either dialysis or hemofiltration. Methods of use of the sterile calcium free low bicarbonate dialysis concentrate compositions are also disclosed. The low bicarbonate concentrate takes... Agent: Ivor M. Hughes, Barrister & Solicitor, Patent & Trademark Agents

20080044491 - Metal-containing formulations and methods of use: Metal-containing materials, as well as their preparation, formulations, and use are disclosed.... Agent: Fish & Richardson PC

20080044492 - Microbicidal compositions: There are described the use of α-(4-chlorophenyl)-α-(1-cyclopropylethyl)-1H-1,2,4-triazole-1-ethanol as a microbicide for the protection of industrial materials, and compositions containing this compound.... Agent: Norris, Mclaughlin & Marcus, Pa

20080044493 - Agent for ameliorating the maximum passage time through digestive tract, agent for ameliorating passage time through digestive tract and preventive for colon cancer: The present invention provides food or preventive drugs whereby food residues retained in the digestive tract over a long period of time due to, for example, overeating even in a healthy person not suffering from constipation and having regular defecation can be discharged by elevating the transit speed without showing... Agent: Posz Law Group, PLC

20080044494 - Skin care compositions containing silicone elastomers: The present invention relates to a topical skin care composition having improved aesthetics containing a pentapeptide, a tacky solvent, and a dermatologically acceptable delivery system containing the tacky solvent in combination with a silicone elastomer and a carrier for the elastomer. The present invention also relates to methods of using... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080044496 - Arthritis phyto-nutraceutical synergistic composition: A Phytoceutical composition for the prevention and treatment of arthritis is provided. A specific combination of extracts of plants and nutraceuticals is taught, as well as principles for varying the formulations based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants... Agent: Jose Olalde Rangel

20080044495 - Extract of plant dendrobii caulis and preparing process thereof: An extract of plant Dendrobii Caulis and preparing process thereof are provided. A physiologically active extract of a plant Dendrobii Caulis and the method thereof are provided in the present invention. The extract is obtained by an extraction of the plant or parts thereof with a water miscible organic solvent... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20080044497 - Methods and pharmaceutical compositions useful for treating psoriasis: Pharmaceutical or cosmetic compositions including cruciferous plant extract or isothiocyanates such as 4-methyl-thio-butyl-isothiocyanate which are useful for treating psoriasis are provided.... Agent: Martin D. Moynihan Prtsi, Inc.

20080044498 - Therapeutic or prophylactic agent, and method of treating or preventing a disease: The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed for treating or preventing a disease accompanying an abnormality in an amount of insulin or insulin... Agent: Birch Stewart Kolasch & Birch

20080044499 - Sleep improvement composition: An object of this invention is to provide a sleep improvement composition, which contains theanine and other components and can be used safely by anybody on a daily basis without side effects. This object is attained by a sleep improvement composition comprising: (a) theanine; and (b) at least one component... Agent: Burr & Brown

20080044500 - Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent: 3-O-β-D-Glucopyranosyl-4-methylergost-7-en-3-ol or a composition containing 0.001% by mass or more of the aforementioned compound, which is an extract of a plant of the family Liliaceae containing the compound or a fraction thereof, is used as an active ingredient of a hyperglycemia improving agent.... Agent: Knobbe Martens Olson & Bear LLP

20080044501 - Fermented soybean products and methods of producing them: Disclosed are fermented soybean protein products with enhanced enzyme productivity and methods for producing them by solid fermentation using Bacillus subtilis GR-101 and additionally Aspergillus oryzae GB-107 (KCTC 10258BP). A novel Bacillus subtilis GR-101 strain (KCCM 10673P), which has excellent protease productivity in soybean meal, is also disclosed. Fermentation using... Agent: Jones Day

20080044502 - Use of an aqueous or hydroalcoholic extract of bauhinia for the preparation of a composition: The present invention relates to a composition comprising an aqueous or hydroalcoholic extract of bauhinia and to the use of an aqueous or hydroalcoholic extract of bauhinia for the preparation of a composition for the care, preservation or improvement of the general state of the skin or hair, for the... Agent: Millen, White, Zelano & Branigan, P.C.

20080044503 - A method for producing functional food aimed at blood pressure reduction from the hydrolyzed vegetable solution: The present invention of “A method for producing functional food aimed at blood pressure reduction from the hydrolyzed vegetable solution, relates to study and develop methods for producing high-performance Angiotensin Convening Enzyme Inhibitor (ACEI) from vegetables by the following production, processes, such as washing, drying, powdering, ultrasonic extraction, vacuum concentration,... Agent: Leong C Lei

20080044504 - Pomegranate juice, pomegranate juice powder and process for producing the powder: A pomegranate juice with enhanced estrogen-like activity per unit amount, a pomegranate juice powder, a process of producing the powder, and foods, feeds, pharmaceutical compositions and the like containing the powder. A pomegranate juice containing substantially no glucose and no fructose; a pomegranate juice containing not more than about 50%... Agent: Fitch, Even, Tabin & Flannery

20080044505 - Nelumbinis semen extract for preventing and treating ischemic heart disease and pharmaceutical composition and health food containing the same: The present invention relates to an Nelumbinis semen extract having the effect of preventing or treating ischemic heart disease, as well as a pharmaceutical composition and health food for the prevention or treatment of ischemic heart diseases, which contain the Nelumbinis semen extract. The inventive Nelumbinis semen extract and the... Agent: Ipla P.A.

20080038190 - Composition apparatus and method for use in imaging: In one embodiment, a composition comprises a microparticle including a radioactive isotope and an imageable element. In another embodiment, a method includes forming a microparticle including a target isotope and an enriched paramagnetic isotope, and transforming the target isotope into a radioactive isotope. In yet another embodiment, an apparatus includes... Agent: Viksnins Harris & Padys Pllp

20080038191 - Radiolabeled compounds and compositions, their precursors and methods for their production: Positron emitting compounds and methods of their production are provided. The compounds have the formula: (F)m G (R)n wherein each R is a group comprising at least one carbon, nitrogen, phosphorus or sulfur atom and G is joined to R through said carbon, nitrogen, phosphorus or sulfur atom; G is... Agent: Christie, Parker & Hale, LLP

20080038194 - System and method for expression proteomics based on isotope ratio modification: The present invention relates to modification of isotope ratios in peptides and polypeptides as an alternative to full isotopic exchange for coding in proteomics. Subtle modification of isotope ratio does not compromise protein identification experiments and can thus provide elemental composition data for accurate isotope ratio decoding. Application of subtle... Agent: Davis Wright Tremaine LLP/los Angeles

20080038198 - Method of screening molecule associated with psychiatric disorder: A method for screening a gene relating to a psychiatric disorder such as schizophrenia, which comprises the step of using a nematode behaviorally sensitized with amphetamine, methamphetamine, apomorphine, cocaine or the like for screening of a gene relating to the behavioral sensitization, and a method for screening a substance useful... Agent: Greenblum & Bernstein, P.L.C

20080038203 - Compositions and methods for topical diagnostic and therapeutic transport: Compositions and therapeutic methods are provided that are useful agent for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGE The compositions and methods are particularly useful for topical delivery of antifungal agents and... Agent: King & Spalding

20080038204 - Whole body imaging using portable observation systems: Methods to image a fluorescent protein in intact subjects using simple portable instruments are described.... Agent: Morrison & Foerster LLP

20080038206 - Product release system for atomizing compositions containing hair-keratin-reducing or oxidative active ingredients: A product release system for atomizing compositions is described, which has (a) a pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing composition. The atomization occurs using the capillary and the composition contains at least one reactive agent, which is selected from hair-keratin-reducing compounds or is selected from... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080038209 - Nicotine delivery product and method for producing it: A nicotine delivery product comprising the reaction product of a nicotine/cation exchange resin complex and an organic polyol; and a method for preparing it comprising (a) mixing an aqueous suspension of a nicotine/cation exchange resin complex with an organic polyol or an aqueous solution thereof, and (b) removing water from... Agent: Merchant & Gould PC

20080038216 - Personal care composition: Personal care composition comprising from about 0.1% to about 15% of an emulsifying silicone elastomer; from about 0.1% to about 40% of at least one solidifying agent; from about 1% to about 75% of an aqueous phase; from about 0.1% to about 74% water; wherein the composition is in the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080038225 - Triazolyl acyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080038226 - Culture methods for cryptosporidium: A host-cell free method for culturing Cryptosporidium comprising the step of introducing Cryptosporidium, at a first lifecycle stage, into a host-cell free medium under conditions which enable the Cryptosporidium to progress to a second lifecycle stage.... Agent: Marshall, Gerstein & Borun LLP

20080038234 - Bone marrow-related cells associated with tissue maintenance and/or repair: The present invention provides transformed bone marrow-related cells that are associated with tissue maintenance and/or repair. Further, the invention provides methods for diagnosing and treating diseased tissues using the transformed bone marrow-related cells. The transformed bone marrow-related cells of the present invention are transformed bone marrow-related cells that are introduced... Agent: Clark & Elbing LLP

20080038228 - Method: The present invention relates to the use of a microorganism and/or a metabolite thereof to at least increase the amount of a COX-1 mRNA in a cell. The present invention further relates to the use of a microorganism and/or a metabolite thereof in the manufacture of a medicament to treat... Agent: Steptoe & Johnson LLP

20080038239 - Method for treating and/or preventing intestinal bacterial imbalance: The present invention provides a method for treating or preventing intestinal bacterial imbalance (IBI) in a mammal. The method includes orally administering a composition comprising germination activated sporoderm-broken Ganoderma lucidum spore powder (“GLSs”) or a mixture of GLSs and beneficial intestinal bacteria, such as Lactobacillus bifidus, to a mammal suffering... Agent: Andrews Kurth LLP Intellectual Property Department

20080038240 - Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption: The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.... Agent: Ingrid A. Beattie Mintz, Levin, Cohn, Ferris, Glovsky And Popeo

20080038229 - Intracoronary injection of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium: The present invention is a method for improving cardiac function and myocardial regeneration in living subjects after the occurrence of myocardial infarction. The method is a combination stem cell therapy involving a mixture of bone marrow-derived mesenchymal stem cells and bone marrow derived mononuclear cells surgically implanted by using either... Agent: Tca Cellular Therapy, LLC Attn: Vicki L. Nicely

20080038244 - Materials and methods relating to cell cycle control: A screen using RNAi methods was used to test the entire set of protein kinases in Drosophila for an effect on mitosis. Most kinases previously known to be involved in the cell cycle were identified, providing validation of the approach. A mitotic function was found for a number of kinases... Agent: Dann, Dorfman, Herrell & Skillman

20080038189 - Rna interference mediated inhibition of aurorakinase b and its combinations as anticancer therapy: This invention relates to the use of short nucleic acid molecules that modulate Aurora-B kinase (AurkB) expression. The invention includes compounds, compositions and methods useful for the modulation of expression and activity of genes involved in the AurkB pathway. In one embodiment, the present invention provides short nucleic acid molecules,... Agent: Foley And Lardner LLP Suite 500

20080038193 - Antibodies for use in targeted and temporary treatment of humans and animals: Described is an antibody, or a fragment of an antibody, which binds to an epitope under specifically chosen conditions, and the binding of which to that epitope is broken under specifically chosen different conditions, in addition to an antibody or fragment thereof with which a diagnostically, therapeutically or cosmetically active... Agent: Trask Britt

20080038192 - Diagnostic methods of multiple organ amyloidosis: Described are methods of assessing whether a subject has or is at risk of having multiple organ amyloidosis (MOA) The method includes detecting a diagnostically predictive collection of biomarkers of multiple organ amyloidosis, wherein the detection of a diagnostically predictive collection of biomarkers indicates the subject has or is at... Agent: Lahive & Cockfield, LLP

20080038195 - Stryrylpyridine derivates and theur use for binding and imaging amylod plaques: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a... Agent: Woodcock Washburn LLP

20080038197 - Method and apparatus for representing myocardial tissues in different states of damage: The invention relates to a method for differentially representing myocardial tissue in different states of damage, comprising the following steps: administering a myocardium-suitable contrast agent to a patient under examination; entering at least one patient-specific parameter affecting the speed of uptake by and elimination from the myocardium of said contrast... Agent: Siemens Corporation Intellectual Property Department

20080038196 - Standardization of botanical products utilizing biological activity as a marker: The present invention relates generally to herbal materials and methods for making such materials in medicinally useful and pharmaceutically acceptable forms. Particularly, the present invention relates generally to Hydrastis canadensis (goldenseal) materials and methods for making such materials in medicinally useful and pharmaceutically acceptable forms. More particularly, the present invention... Agent: Bio Intellectual Property Services (bio Ips) LLC

20080038202 - Controlling osteogenesis by inhibition of osteogenic suppressors: The present invention provides methods of screening for agents that inhibit the activity or expression of one or more polypeptides that contribute to the suppression of osteogenesis. The invention also provides methods of inducing osteogenesis in a cell by administering to the cell an agent that inhibits one or more... Agent: Townsend And Townsend And Crew, LLP

20080038201 - Global regulator of morphogenesis and pathogenicity in dimorphic fungi and uses thereof: A method of screening a compound for anti-fungal properties comprising the steps of exposing a test compound to a fungal histidine kinase, and determining whether kinase activity is inhibited, wherein inhibition of kinase activity indicates that the compound has anti-fungal properties is disclosed.... Agent: Quarles & Brady LLP

20080038199 - Methods related to the treatment of neurodegenerative and inflammatory conditions: The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of... Agent: Merchant & Gould PC

20080038200 - Model for neurodegenerative diseases involving amyloid accumulation: The present invention provides brain cells, such as normal brain cells, apolipoprotein E deficient brain cells, or apoE4 containing brain cells, that are treated with a compound which can modulate integrins and/or integrin receptors to produce increased sequestration of and/or accumulation of and/or uptake of Aβ, and/or changes in cathepsin... Agent: Beyer Weaver LLP

20080038205 - Novel dermatophagoides proteins: The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.... Agent: Heska Corporation Legal Department

20080038207 - Method and device for decreasing contamination: Methods and devices to determine rate of particle production and the size range for the particles produced for an individual are described herein. The device (10) contains a mouthpiece (12), a filter (14), a low resistance one-way valve (16), a particle counter (20) and a computer (30). Optionally, the device... Agent: Edwards Angell Palmer & Dodge LLP

20080038208 - Pharmaceutical/cosmetic compositions comprising the lysine-d-proline-valine tripeptide: Pharmaceutical/cosmetic compositions comprising a therapeutically effective amount of at least one peptide containing the lysine-proline-valine tripeptide sequence, the proline moiety of which existing in its dextrorotatory optical isomer form (DPro), or functional biological equivalent thereof, are well suited for the treatment of inflammation disease states afflicting a mammalian subject.... Agent: Buchanan, Ingersoll & Rooney PC

20080038210 - Liquid compositions for oral cavity: The present invention relates to a liquid composition for the oral cavity, which contains the following components (A), (B), (C) and (D): (A) an oil-soluble flavor, (B) a cationic bactericide, (C) a sugar fatty acid ester, and (D) one or more compounds selected from the group consisting of polyglycerol fatty... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080038211 - Tooth whitening strips: A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080038212 - Herbal mixture extract of pleurotus eryngii, acanthopanacis cortex and notoginseng radix and a composition comprising the same for prevention and treatment of periodontitis: The present invention relates to a herbal mixture extract of Pleurotus eryngii, Acanthopanacis Cortex and Notoginseng Radix and a composition for prevention and treatment of periodontal disease containing the herbal mixture extract as an active ingredient, more precisely, a herbal mixture extract having activities of inhibiting the generation and activation... Agent: Joseph Hyosuk Kim, Ph.d. Jhk Law

20080038214 - High concentration dinotefuran formulations: A topical insecticide is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. In one preferred embodiment of the invention, the active ingredient of the insecticide formulation is an amine derivative, having a nitro-methylene group, a nitroamino group or a cyanoamino... Agent: Stroock & Stroock & Lavan LLP

20080038213 - Uv filters: The invention relates to compounds of the formula (I) or (II), to compositions which comprise such compounds, to corresponding processes for the preparation of the compounds or the compositions comprising same, and to the use thereof as light-protection filters.... Agent: Millen, White, Zelano & Branigan, P.C.

20080038215 - Hair care composition comprising a dendritic macromolecule: A cosmetic and personal care composition comprising a hydrophobically functionalised dendritic macromolecule.... Agent: Unilever Intellectual Property Group

20080038217 - Cosmetic composition comprising at least one silicone/acrylate copolymer and at least one nonionic polymer comprising at least one vinyllactam unit: The present invention relates to cosmetic compositions comprising at least one specific silicone/acrylate copolymer and at least one nonionic polymer comprising at least one vinyllactam unit. The present invention is also directed to a processes, in particular a process for fixing and/or holding the hairstyle comprising the in use of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080038218 - Cosmetic composition comprising at least one electrophilic monomer, at least one fluoro compound and at least one liquid organic solvent: The present disclosure relates to a cosmetic composition for treating keratin fibers, for instance human keratin fibers such as the hair, comprising at least one liquid organic solvent, at least one electrophilic monomer and at least one organofluorine compound comprising at least 4 carbon atoms, with the exception of polytetrafluoroethylene,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080038219 - Novel composition for a topical skin treatment base and medicated applications thereof: A novel topical preparation comprised of carboxylic acids, chelating agents, dimethyl Sulfone and magnesium sulfate that forms a functional and versatile base formation for the addition of numerous medications and active ingredients for the purpose of treating certain skin conditions including, but not limited to psoriasis, eczema, dermatitis, acne, rosacea,... Agent: Jim Mosbaugh Calgenex Corporation

20080038220 - Testosterone gels comprising propylene glycol as penetration enhancer: The present invention relates to testosterone-containing pharmaceutical compositions and gels, and to methods using the same.... Agent: Foley And Lardner LLP Suite 500

20080038221 - Method for producing protein adsorption-preventing ocular lens material: e

20080038222 - Composition comprising colony stimulating factor for treatment of a localised bacterial infection and bacterial related disease: The invention provides a composition for treatment of a localized bacterial infection comprising at least one CSF or fragment or derivative thereof. Also provided is the use of at least one colony stimulating factor (CSF) or fragment or derivative thereof having essentially the biological functionality and activity of the CSF... Agent: Fish & Richardson P.C.

20080038223 - Wsx-1/p28 as a target for anti-inflammatory responses: Compositions and methods relating to WSX-1 and p28 (IL-30) are provided. In particular, methods of treating inflammatory conditions in mammalian subjects using various WSX-1, p28, EBI3, and gp130 polypeptides and complexes or moieties that bind to or modulate activity of such complexes are described. Isolated or recombinant complexes including soluble... Agent: Quine Intellectual Property Law Group, P.C.

20080038224 - Modified interferon-beta (ifn-beta) polypeptides: Provided are modified interferon-beta polypeptides and nucleic acid molecules encoding modified interferon-beta polypeptides and formulations containing the polypeptides and/or nucleic acid molecules. The modified polypeptides exhibit increased protein stability, including increased resistance to proteases. Also provided are methods of treatment by administering modified interferon-beta polypeptides.... Agent: Fish & Richardson, PC

20080038227 - Animal model of neurodegenerative diseases, the procedure for producing the model and applications thereof: The present invention relates to the field of diseases, such as Alzheimer's disease, where abnormal brain accumulation of β amyloid and/or amyloid plaques are involved. More specifically, the present invention relates to a non-human animal model for such diseases and its use in screening methods for molecules for treating same.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080038236 - Biocompatible scaffolds and adipose-derived stem cells: The present invention relates to compositions of biocompatible materials and adult stem cells. The present invention also provides methods of alleviating or treating bone defects or soft tissue defects using the compositions.... Agent: Seed Intellectual Property Law Group PLLC

20080038238 - Human stem cell materials and methods: Monocyte derived adult stem cells (MDSCs) isolated from peripheral blood of mammals is provided, along with pharmaceutical compositions containing an MDSC, kits containing a pharmaceutical composition, and methods of preparing, propagating and using MDSCs or differentiated derivatives thereof. The uses of these biological materials include methods of treating disorders or... Agent: Marshall, Gerstein & Borun LLP

20080038235 - Methods for regulating t cell subsets by modulating transcription factor activity: Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of one or more transcription factors that cooperate with NF-AT family proteins to regulate expression of a Th2-associated cytokine gene are disclosed. In one embodiment, the activity of a maf family... Agent: Lahive & Cockfield, LLP

20080038233 - Treatment of spinal conditions: The invention relates to isolated mesenchymal stromal stem cell (MSSC) that has been differentiated in vitro towards, or to, an intervertebral disc (IVD) cell phenotype for use as medicaments. The cells may be used to treat spinal conditions characterized by degeneration of the intervertebral disc. The cells may also be... Agent: Davis Wright Tremaine LLP/los Angeles

20080038237 - Trojan horse immunotherapy: The present invention provides methods for the delivery of therapeutic proteins to an area of inflammation and neuronal damage within the central nervous system (CNS). In this invention, immunocytes that can cross the blood brain barrier and access sites of CNS injury/inflammation, are genetically engineered to express and secrete a... Agent: Bozicevic, Field & Francis LLP

20080038230 - Method of cell isolation: The present invention relates generally to a method for the generation of a substantially homogenous population of undifferentiated cells. More particularly, the present invention relates to a method for isolating a substantially homogenous population of stem cells, and in particular, mammary stem cells (MaSCs). The MaSCs of the present invention... Agent: Knobbe Martens Olson & Bear LLP

20080038231 - Processing procedure for peripheral blood stem cells: An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or “pre-disease” state, for future distribution for his... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080038232 - Production of high mannose proteins in plant culture: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes... Agent: Martin D. Moynihan Prtsi, Inc.

20080038241 - Self-polishing anti-fouling coating compositions comprising an enzyme: The present invention relates to self-polishing, anti-fouling coating compositions comprising an enzyme, methods for producing such coating compositions and uses thereof. The coating composition can comprise e.g. a pigment in which case the coating composition can be used as a painting composition. In a first aspect, the invention relates to... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080038242 - Benzimidazole derivatives and medical uses thereof: In the formula, n is 1 or 2; R1 and R2 are H, a halogen atom, cyano group, optionally substituted alkyl group, optionally substituted aryl group or the like; R3 is H, a halogen atom, optionally substituted alkyl group or the like; R4 and R5 are H, a halogen atom,... Agent: Frenkel & Associates

20080038243 - Wound healing compositions and methods using tropoelastin and lysyl oxidase: The present invention provides compositions and methods for promoting wound healing. The composition comprises virgin monomers of tropoelastin and lysyl oxidase. When the lysyl oxidase comes in contact with the tropoelastin, cross-linking of the tropoelastin monomers will occur to form elastin. Contacting the tropoelastin and lysyl oxidase together and applying... Agent: Seed Intellectual Property Law Group PLLC

20080038246 - Crystallized oxalate decarboxylase and methods of use: Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.... Agent: Fish & Richardson PC

20080038245 - Methods of modulating angiogenesis: Method of modulating angiogenesis in a cell, tissue or subject and methods of treating an angiogenesis-related disorder include modulating PKCβ activity.... Agent: Fish & Richardson PC

20080038247 - Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39): The invention provides a human GPR39 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of... Agent: Banner & Witcoff, Ltd.

20080038252 - Histamine-containing composition for the treatment of allergic diseases: The present invention provides a pharmaceutical composition comprising histamine, immunoglobulin and allergen as active ingredients. Also, the present invention provides a kit for treating allergic diseases comprising the above active ingredients. The present invention also provides use of a composition comprising histamine, immunoglobulin and allergen as active ingredients for the... Agent: The Rafferty Patent Law Firm

20080038251 - Mn/ca ix and mapk inhibition: The invention is based upon the discovery that the mitogen-activated protein kinase (MAPK) pathway can increase CA9 expression independently of HIF-1, as well as increasing CA9 expression under HIF-1-dependent pathways initiated by hypoxia or high cell density. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal... Agent: Leona L. Lauder Attorney At Law

20080038250 - Profilin and related immunomodulatory ligands: The invention provides profilin-related immunomodulatory polypeptides and toll-like receptor agonists, as well as related pharmaceutical compositions and methods of treatment, useful for treating cancer and infectious disease.... Agent: Wilmerhale/boston

20080038248 - Proteins ligands for nkg2d and ul16 receptors and uses thereof: A novel member of the RAET1/ULBP family of proteins (RAET1G) is identified and characterised and shown to bind the UL16 and NKG2D receptors with high affinity. RAET1G exhibits restricted expression in normal tissues but exhibits high levels of expression in tumours and may be differentially spliced in cancer cells to... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080038249 - Treatment of neurodegenerative diseases by the use of laptm4a: The invention relates to the use of a LAPTM4A-interacting molecule for the preparation of a pharmaceutical composition for the treatment of a neurogenerative disease. Hereby the LAPTM4A-interacting molecule is preferably an inhibitor of LAPTM4A and particularly it has the capacity to modulate the activity of gamma-secretase and/or beta-secretase. Furthermore the... Agent: Clark & Elbing LLP

20080038254 - Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies,... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080038253 - Methods for altering t cell diversity: Methods and materials for enhancing T cell diversity are described. For example, methods that include administering purified populations of B cells or immunoglobulins to subjects in need thereof are provided.... Agent: Fish & Richardson P.C.

20080038256 - Anti-hgf/sf humanized antibody and method for the preparation thereof: The inventive anti-HGF/SF humanized antibody prepared by displaying on the surface of a phage an anti-HGF/SF chimeric Fab library comprising a set of human antibody light chain variable region (VL) and human antibody heavy chain variable region (VH) which are grafted with heavy chain complementary determining regions (HCDRs) of an... Agent: Sughrue Mion, PLLC

20080038261 - Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.... Agent: Sidley Austin LLP Attn: Dc Patent Docketing

20080038257 - Hepatocyte growth factor (hgf) binding proteins: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain... Agent: Goodwin Procter LLP Patent Administrator

20080038262 - Humanized neutralizing antibodies against hemolytic uremic syndrome: Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080038260 - Ilt3 binding molecules and uses therefor: The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). The binding molecules of the invention are characterized by binding to hILT3 with high affinity and... Agent: Lahive & Cockfield, LLP

20080038259 - Lfa-1 alpaha subunit antibodies and methods of use: Antibodies useful for and methods of treating LFA-1 alpha subunit associated physiological conditions and diseases treatable with an antibody that binds LFA-1 alpha subunit, such as HIV, are provided.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080038263 - Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas: Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical... Agent: Jones Day

20080038258 - Polypeptides with reduced susceptibility to oxidation and methods of making: The present invention relates in general to polypeptides having reduced susceptibility to oxidation, methods of selecting or making the polypeptides and methods of use thereof. The polypeptides having reduced susceptibility to oxidation are modified by amino acid substitution, deletion or insertion to confer reduced susceptibility to oxidation, thereby decreasing degradation... Agent: Marshall, Gerstein & Borun LLP

20080038255 - Splice variant of unc5h2: The present invention provides an UNC5H2 splice variant polypeptide, UNC5H2d, and the nucleic acid molecule encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing the UNC5H2d polypeptide. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080038265 - Antibodies to erythropoietin receptor and uses thereof: The present invention relates to antibodies and antigen-binding portions thereof that bind to and activate an erythropoietin receptor. The invention also relates to nucleic acid sequences encoding such antibodies and antigen-binding portions. The present invention further relates to methods of activating the endogenous activity of an erythropoietin receptor in a... Agent: Robert Deberardine Abbott Laboratories

20080038264 - Compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20080038269 - Methods for detecting and treating kidney disease: A method is provided for diagnosing and monitoring kidney disease or a predisposition to kidney disease, in a subject comprising detecting pVHL, VEGF-A, CXCR4, integrin β-1, PDGF-A, HIF1α and/or TGFβ in a sample from the subject. Screening methods for test agents for inhibiting kidney disease, and therapeutic applications are also... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080038268 - Streptococcus pyogenes antigens: The present invention relates to antigens, more particularly an antigen of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which is useful as vaccine component for therapy and/or prophylaxis.... Agent: Seed Intellectual Property Law Group PLLC

20080038266 - Treatment for bacterial infections: The present invention is concerned with compounds, medicaments and treatments for Clostridium difficile infection, together with novel isolated antibodies and their use in same. The present invention is also concerned with the treatment and prophylaxis of E. faecium and E. faecalis infection and provides medicaments and treatments for same.... Agent: Fish & Richardson PC

20080038267 - Treatment of cancer: The present invention relates to a novel medicaments and preparations comprising effective anti-cancer agents together with an anti-Hsp90 antibody which together provide an enhanced efficacy in the treatment of cancer, and leukaemia.... Agent: Fish & Richardson PC

20080038270 - Antibody specific for a chondroitin sulphate epitope: An antibody specific for a chondroitin sulphate epitope is described, as is a hybridoma cell line which produces such an antibody. The antibody is useful in the diagnosis and treatment of connective tissue diseases, such as arthritis and sarcomas. Test kits and pharmaceutical compositions are also described.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080038271 - Extending survival of cancer patients with elevated levels of egf or tgf-alpha: The present application describes extending survival in a cancer patient, where the patient is producing an elevated level of EGF or TGF-alpha, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.... Agent: Heller Ehrman LLP

20080038272 - Monoclonal antibody against frizzled receptors: The present invention relates to a monoclonal antibody or fragment thereof, which binds specifically and/or selectively to human receptors of the Frizzled (FZD) family. It further relates to a hybridoma cell that produces the antibody according to the invention. Another object of the present invention is a method for the... Agent: Morrison & Foerster LLP

20080038273 - Anti-cd28 antibody: The invention concerns an antibody directed against the CD28 receptor and capable of blocking CD28/B7 interaction, and proteins derived from said antibody, for use in particular to block CD28-dependent activation of lymphocytes.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080038274 - Inhibition of secretion from non-neuronal cells: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of... Agent: Merchant & Gould PC

20080038275 - Method for the treatment of multiple sclerosis: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with... Agent: Klarquist Sparkman, LLP

20080038276 - Inhibitors of plasma kallikrein: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.... Agent: Townsend And Townsend And Crew, LLP

20080038277 - Dna pkinase inhibitors for treating cancer and diabetes: Methods of treating disorders associated with the PKB signalling pathway, such as cancer, diabetes, and neurodegenerative disorders, are provided. The methods comprise modulating the activity of DNA-PK; this enzyme has been identified as having serine 473 kinase activity. Compositions comprising DNA-PK or modulators thereof are also provided for use in... Agent: Novartis Corporate Intellectual Property

20080038278 - Gpat3 encodes a mammalian, microsomal acyl-coa:glycerol 3- phosphate acyltransferase: The present invention provides isolated and purified polynucleotides and polypeptides related to mouse and human microsomal acyl-CoA:glycerol 3-phosphate acyltransferase 3 (GPAT3) and their uses in modulating triacylglycerol (TAG) levels in a cell or sample of interest. The invention also provides GPAT3 agonists and antagonists, e.g., GPAT3 polynucleotides and polypeptides, antibodies... Agent: Fitzpatrick Cella (wyeth)

20080038279 - Composition for treating pathology associated with msrv/herv-w: The inventive composition comprises at least one type of antibody selected in a group (i) of anti-Env-SU MSRV/HERV-W antibodies or in a group of anti-TLR4 antibodies specifically linkable with the soluble fraction of an Env protein of MSRV/HERV-W or to a TLR4 receptor of the soluble fraction of the Env... Agent: Oliff & Berridge, PLC

20080038282 - Biotinylated mhc complexes and their uses: The invention demonstrates an improved choice of biotinylation peptide to be used in a combination or fusion with an MHC molecule for immobilizing or multimerising such MHC molecules for a variety of purposes.... Agent: The Fleshner Group, PLLC

20080038280 - A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines: The invention provides a fusion protein, which comprises an antigen binding portion of an A32 human antibody, or variant thereof, and one of the following: (a) an antigen-binding portion of a second antibody or variant thereof, wherein the second antibody binds to an epitope of an envelope protein of a... Agent: Leydig, Voit & Mayer, Ltd.

20080038281 - Model membrane systems: The present invention relates generally to modifying biological and/or synthetic membranes or liposomes, or combinations thereof, for the purpose of altering immunity, or for the targeting of drugs and other agents to a specific cell type or tissue when administered in vivo to achieve a therapeutic effect. Modification of the... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080038284 - Human immunodeficiency virus vaccine: The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine.... Agent: Nixon & Vanderhye, PC

20080038283 - Methods of evaluating efficacy of an immune response by assesing alpha-1 integrin expression: Disclosed are compositions and methods evaluating efficacy of an immune response by assessing alpha-1 integrin, screening for, and manufacturing those therapeutic agents. Described herein the presence of VLA-1+ (positive) T cells indicates an effective immune response. Also disclosed are methods of screening for antigens that induce the production of VLA-1+... Agent: Needle & Rosenberg, P.C.

20080038285 - Method for identifying and quantifying of tumour-associated: Described is a method for identifying and quantifying of tumour-associated peptides, wherein first at least two different sources for obtaining the peptide are provided (tumourous and healthy tissue), and, separately of one another, the peptides from the different sources are chemically modified in an identical manner by using at least... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080038286 - Glycosylated polypeptides produced in yeast mutants and methods of use thereof: The invention provides various high mannose glycosylated polypeptides that are useful in a vaccine formulations. The invention also provides methods for making such glycosylated polypeptides and its uses in eliciting HIV-neutralizing antibodies.... Agent: Morrison & Foerster LLP

20080038287 - Method for identification, isolation and production of antigens to a specific pathogen: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized... Agent: Fulbright & Jaworski L.L.P.

20080038288 - Prevention of damage in hippocampus of fetus/newborn infant due to maternal gestational hypertension: The present invention provides a method for preventing or ameliorating neural damage in a mammalian fetus or a newborn infant, which is caused by maternal gestational hypertension (GH). The method includes orally administering germination activated sporoderm-broken Ganoderma lucidum spores (“GLSs”) to a pregnant mammal having GH. The neural damage includes... Agent: Andrews Kurth LLP Intellectual Property Department

20080038289 - Antitumor agent: According to the present invention, an antitumor agent, an apoptosis-inducing agent or an angiogenesis-suppressing agent having the effect even via an oral route, containing a compound contained in an inexpensive edible basidiomycete or a composition derived from an edible basidiomycete, and a food having the antitumor activity, the apoptosis-inducing activity... Agent: Birch Stewart Kolasch & Birch

20080038290 - Cosmetic slimming composition containing an extract of biomass of the alga neochloris oleoabundans: The invention relates to a cosmetic composition comprising, as active agent, an extract of biomass of the alga Neochloris oleoabundans, said active agent being incorporated in a cosmetically acceptable vehicle compatible with topical application. This extract is advantageously an alcoholic or aqueous-alcoholic extract, called the first extract, obtained by treating... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080038291 - Method to reduce the physiologic effects of drugs on mammals: A method to reduce the physiologic effects of drugs in vivo by inducing specific anti-drug antibodies using drugs conjugated to carrier molecules so as to reduce a drug's toxicity and its physiologic effects upon the recipient. This method includes the treatment and prophylactic prevention of drug abuse, specifically for cocaine... Agent: Jones Day

20080038292 - Liquid growth hormone formulation: The invention relates to a liquid formulation comprising a growth hormone or a substance, which stimulates release or potentiates the activity of endogenous hGH; a polyethylene-polypropylene glycol; a citrate/phosphate buffer, an alkali metal salt and an alkaline earth metal salt or a pseudo alkaline earth metal salt, and to a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080038293 - Prrsv subunit vaccines: Vaccines effective against PRRSV include at least one portion of PRRSV ORF1. Such vaccines, upon administration, provoke an immune response in PRRSV-susceptible animals. Moreover, compositions in accordance with the present invention provide immune response up to and including protective immunity against PRRSV as well as reduce the severity of PRRSV... Agent: Hovey Williams LLP

20080038294 - Intranasal or inhalational administration of virosomes: The present invention provides a composition of influenza virosomes comprising reconstituted envelopes of said virus, wherein the viral envelopes are entirely derived from influenza viral particles, wherein no lipid is added from an external source to the reconstituted virosomes, wherein the virosomes comprise the influenza antigens haemagglutinin and/or neuraminidase or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080038295 - Compositions and methods for orthopox virus vaccination: The present invention relates to methods and compositions for stimulating an immune response. Specifically, the present invention provides methods of inducing an immune response to an orthopox virus (e.g., vaccinia virus) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising vaccinia virus).... Agent: Casimir Jones, S.c.

20080038296 - Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and... Agent: Foley And Lardner LLP Suite 500

20080038297 - Genetic adjuvants for viral vaccines: The present invention relates to compositions and methods to improve expression of exogenous polypeptides, such as an antigen, epitope, immunogen, peptide or polypeptide of interest, in viral vaccines. More particularly, the present invention provides for viral vaccines with increased adjuvantation via a genetic adjuvant.... Agent: Frommer Lawrence & Haug

20080038298 - Medicament and system for the percutaneous preparation of medicaments: The invention relates to an application system provided with a micro emulsion (14) containing a medication, said micro emulsion being contained in a medicament reservoir (12), a first gas connection (18) to which oxygen can be guided, a nozzle head (28) comprising recesses (29) which are arranged on the end... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080038302 - Collapsible water-containing capsules: Collapsible water-containing capsules comprising by weight: (A) from about 70% to about 92% of a water phase comprising, by weight of the capsule, (1) from about 5% to about 91.9% water and (2) from about 0.1% to about 20% of a gelling agent; (B) from about 1% to about 29.9%... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080038301 - Personal care product comprising collapsible water-containing capsules: A personal care product comprising: (a) a collapsible water-containing capsule having water encapsulated or dispersed in a first pigment component which is a hydrophobic pigment having a particle size of less than 1 μm; and (b) an applicator for applying the capsule on a personal care surface, wherein the surface... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080038300 - Self-adhesive skin patch and combination set for cosmetic skin care: The present invention relates to a skin patch comprising a matrix adhering to the skin and containing at least one active cosmetic substance and a combination with a skin wrapping to generate an effective compression for the treatment of cellulite and/or striae.... Agent: Greenblum & Bernstein, P.L.C

20080038299 - Skincare compositions comprising salicylic acid: There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises alicylic acid or a salt thereof and hydrolysed milk protein. The composition is useful in the treatments of acne.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080038303 - Novel solid compositions for disinfected water: The present invention provides a method for the preparation of water-sanitizing solid, shaped compositions, said method comprising the steps of: mixing a halogenated 5,5-dimethylhydantoin compound or mixture of compounds with a chlorine biocide compound and compacting the mixture into a final single solid composition, by applying a pressing force sufficient... Agent: Kevin D Mccarthy Roach Brown Mccarthy & Gruber

20080038304 - Microencapsulated compositions for topically treating an animal against parasite infestation: The invention provides aqueous liquid dispersions of microcapsules comprising at least one anti-parasitic agent. The microcapsules have a core material that contains one or more anti-parasitic agents. The core material is encapsulated by a shell wall that is substantially hydrophilic and generally does not dissolve in water. The microcapsules may... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080038305 - Ceramic bulking agent: This invention relates to a tissue bulking agent comprising a particulate micro-porous bioinert ceramic material, in the form of spheres, having interconnected pores. Pores on the surface of each sphere are connected to pores inside such sphere via blow-holes and the internal pores are in turn interconnected, so that in... Agent: Nixon & Vanderhye, PC

20080038306 - Fluidic tissue augmentation compositions and methods: Compositions and method for augmenting tissue after delivery to localized area. The compositions include a hydrogel and a dermal filler. The hydrogel can polymerize and/or crosslink upon a first trigger event. The dermal filler can also optionally crosslink upon a second trigger event.... Agent: Wilson Sonsini Goodrich & Rosati

20080038311 - Bone replacement material: A bone replacement material that is, in particular, paste-like and is characterized in that particulate calcium carbonate is suspended in an aqueous solution that contains at least one water-soluble hemostatic agent, whereby the aqueous solution contains an amount of the hemostatic agent at which it is isotonic.... Agent: Norris, Mclaughlin & Marcus, Pa

20080038307 - Biocompatible coating, method, and use of medical surfaces: The invention relates to medical products having a surface that is at least partially covered by a polymer layer. Said polymer layer is preferably formed by auto-polymerization. Substances containing least one multiple bond, especially unsaturated fatty acids comprising an alkyl chain consisting of preferably between 7 and 50 carbon atoms... Agent: J C Patents, Inc.

20080038310 - Coating comprising an elastin-based copolymer: A copolymer comprising a block of an elastin pentapeptide and method of making and using the copolymer are provided.... Agent: Squire, Sanders & Dempsey LLP

20080038314 - Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells: Compositions and methods are provided for treatment of cartilage defects in animals and humans. The compositions of the invention include synovial tissue, synovial cells and matrices containing synovial (or cambium) tissue or cells for use in filling a cartilage defect. The matrix and synovial tissue or cell preparations may also... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080038312 - Insertable or implantable medical devices suitable for gene therapy regimens: An implantable or insertable medical device suitable for gene or cell therapy regimens, and method of making and using same are disclosed. The medical device contains a biocompatible structure carrying a genetic material. The biocompatible structure includes a polymeric coating that coats at least a portion of the structure. The... Agent: Kenyon & Kenyon LLP

20080038308 - Silencing rna molecules and their use in bone formation: The present invention is directed to siRNA molecules that down-regulate the expression of proteins that inhibit bone formation. In another aspect, the instant invention is directed to compositions and/or implants comprising in combination such siRNA molecules in a pharmaceutically acceptable carrier or implant.... Agent: Mcandrews Held & Malloy, Ltd

20080038313 - Systems, methods, and compositions for mixing and applying lyophilized biomaterials: A method of treating tissue lyophilizes a biocompatible polymer having a functionality equal to or greater than three. The method provides a protein solution. The method mixes the protein solution with the lyophilized polymer to reconstitute the polymer and form a mixture, wherein, upon mixing, the protein solution and the... Agent: Daniel D. Ryan Ryan Kromholz & Manion, S.c.

20080038309 - Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-a of hmgb1 to prevent and/or antagonize pathologies induced by hmgb1: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080038315 - Process for agent retention in biological tissues: A method of treatment, including separately delivering a treatment agent and a barrier having a binding member to a tissue, the binding member having a property adapted to couple to a surface of the tissue, wherein the barrier is present in an amount sufficient to permit transport of the treatment... Agent: Blakely Sokoloff Taylor & Zafman

20080038316 - Conveniently implantable sustained release drug compositions: This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.... Agent: Nixon Peabody, LLP

20080038317 - Therapeutic lacrimal canalicular inserts and related methods: Lacrimal canalicular inserts include a polymeric component and a therapeutic component. The therapeutic component is released from the inserts for extended periods of time, such as for more than about 2 weeks after placement in a lacrimal canaliculus of an individual. The polymeric component may include one or more non-biodegradable... Agent: Allergan, Inc.

20080038318 - Composition; use of a composition and a method for treating obesity: The invention relates to the use of a food-approved emulgator in the preparation of a preparation intended for the prevention of fat absorption, to a nutrient composition containing an emulgator for the prevention of fat absorption, and to a functional food characterized in that it contains an effective amount of... Agent: Ladas & Parry

20080038320 - Compositions and methods for enhancing vasodilation: Compositions and methods to achieve vasodilation through nitric oxide production pathways and Angiotensin II inhibition pathways using bovine lactoferrin and whey derived angiotensin converting enzyme inhibiting peptides are provided. Other nitric oxide ingredients may be added as well for sports nutrition applications. Such compositions and methods achieve a “pump”, which... Agent: Banner & Witcoff, Ltd.

20080038321 - Prophylactic/therapeutic compositions for liver diseases: There are provided a prophylactic and/or therapeutic composition for a liver disease which contains an amino acid having an insulin-sensitivity enhancing action as an active ingredient, and a prophylactic and/or therapeutic composition for a liver disease which contains at least one amino acid selected from the group consisting of aspartic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080038319 - Transformed bacteria producing cs6 antigens as vaccines: Disclosed herein are antigens that stimulate protective antibodies against enterotoxigenic Escherichia coli. Also disclosed herein are proteins encoded by cssA and cssB genes as well as constructs containing the genes and methods of using thereof.... Agent: Office Of The Staff Judge Advocate (sks) U.s. Army Med. Research & Materiel Command

20080038323 - Methods for improving liver clearance of xenobiotic substances in an animal: A method for improving liver clearance of xenobiotic substances in an animal by feeding the animal lipoic acid in amounts of from about 10 mg to about 1000 mg per day.... Agent: Colgate-palmolive Company

20080038322 - Stabilized bacteriophage formulations: Stabilized bacteriophage compositions, and methods for preparing stabilized bacteriophage compositions are provided. The method for producing an antibacterial composition involves adsorbing an aqueous solution of one or more bacteriophages, or one or more phage components, onto a matrix to produce a composition, and drying the composition to produce the antibacterial... Agent: Hutchison Law Group PLLC

20080038325 - Therapeutic hydrogel for atopic dermatitis and preparation method there: Disclosed are therapeutic hydrogels for atopic dermatitis and a method for preparing the same. The hydrogels comprises a biocompatible polymer, a polyalcohol, and a medicinal plant extract. The hydrogels can carry medicinally effective ingredients for a sustained period of time and absorb wound exudates properly. The hydrogels have suitable gel... Agent: Lucas & Mercanti, LLP

20080038324 - Sanitary thin paper for domestic use: [Means for Resolution] Hygienic thin paper for household use made of thin paper impregnated with a moisturizing component, wherein at least one member selected from the group consisting of a natural moisturizing factor and an intercellular lipid of a stratum corneum is contained as the foregoing moisturizing component, and a... Agent: Jordan And Hamburg LLP

20080038326 - Multilayered dosing systems: The invention relates to dosing systems which involve water-soluble or water dispersible products containing ingredients embedded within and/or coated upon a water-soluble film which are released at a prescribed rate into an aqueous environment through one or more perforated less readily soluble water-soluble films. The dosing system can be used... Agent: Polster, Lieder, Woodruff & Lucchesi

20080038327 - Wound care products containing keratin: The invention relates to a would care product that provides a biochemical environment around a wound to promote wound healing. The wound care product includes a keratin protein fraction material in which the protein fraction is intact, is from the intermediate filament protein family or the high sulfur protein family... Agent: Bacon & Thomas, PLLC

20080038328 - Pasting preparation: The patch preparation of the present invention is a patch preparation comprising a backing and an adhesive layer provided on the backing; wherein, the adhesive layer contains (A) a volatile organic acid and (B) a basic drug; the molar concentration ratio [(MA)/(MB)] between the molar concentration (MA) of the component... Agent: Nath & Associates

20080038330 - Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds of the lower respiratory tract: Use of an anti-inflammatory agent such as povidone iodine for the preparation of a pharmaceutical composition for the treatment of diseases of the lower respiratory tract which are susceptible to the administration of such agents.... Agent: Jones Day

20080038329 - T-cell activating agent: The present invention provides a T cell activator comprising an antigen-bound phospholipid membrane, wherein the phospholipid membrane comprises a phospholipid having an acyl group having one unsaturated bond and 14 to 24 carbon atoms or a hydrocarbon group having one unsaturated bond and 14 to 24 carbon atoms, and a... Agent: Leydig Voit & Mayer, Ltd

20080038332 - Stable pharmaceutical formulation comprising atorvastatin calcium: The invention relates to a stable pharmaceutical formulation comprising an intimate admixture or admixture of crystalline or amorphous atorvastatin calcium, and a stabilizing-effective amount of a water-insoluble alkaline excipient or a combination of one or more water-insoluble alkaline excipients thereof, a stabilizing-effective amount of an antioxidant or a combination of... Agent: Hui Min He Huang

20080038331 - Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use: Enantiomerically pure S-etifoxine and pharmaceutically acceptable salts, solvates, hydrates or prodrugs thereof are provided. Also provided are pharmaceutical compositions comprising the compounds and methods of treating disorders associated with central nervous system using the compounds and pharmaceutical compositions.... Agent: Jones Day

20080038333 - Formulations for poorly soluble drugs: The present invention provides a drug delivery system comprising nanoparticles or microparticles of a water poorly soluble drug dispersed in a polymeric bead containing essentially only of hydrophilic polymers (i.e. without hydrophobic polymers). The present invention further provides a method of producing the drug delivery system of the invention.... Agent: Nath & Associates

20080038334 - Method for producing and a system for cooling a hot-filled softgel capsule: A system for producing a hot-filled softgel capsule utilizes a chilled liquid. The chilled liquid is routed through a chilled liquid conveyor tray into a chilled liquid bath. The chilled liquid conveyor tray directs the flowing chilled liquid into a flowing chilled liquid layer. Softgel capsules having a heated fill... Agent: Fitzpatrick Cella (catalent)

20080038335 - Method, formulation, and use thereof for improved oral absorption of pharmaceuticals or nutrients: This invention relates to the development of a composition formulation and method employed to alter the absorption site of orally administrated drugs, to promote the absorption of bioactive lipophilic and/or hydrophilic compounds from the gastrointestinal tract, and as a result to increase drug bioavailability. Applications of the methods and formulations... Agent: Matthias Scholl

20080038339 - Solid dosage form comprising solid dispersion and method for producing the same: Provided are a solid dosage form comprising a solid dispersion that allows a drug in the preparation to be rapidly dissolved without compromising the solubility of the solid dispersion, and a method for producing the same. More specifically, provided is a solid dosage form comprising a solid dispersion, the dispersion... Agent: Myers Bigel Sibley & Sajovec

20080038340 - Solid dosage form of enteric solid dispersion and method for producing the same: Provided are a solid dosage form comprising an enteric solid dispersion that allows a drug in the preparation to be rapidly dissolved without compromising the solubility of the solid dispersion, and a method for producing the same. More specifically, provided is a solid dosage form comprising an enteric solid dispersion... Agent: Myers Bigel Sibley & Sajovec

20080038336 - Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent: This invention relates to a solid pharmaceutical composition that include a regulating agent of digestive and/or intestinal motility which has an agonist effect on peripheral μ, δ and κ opiate receptors; and an antiflatulent for the treatment and regulation of intestinal motility and flatulence in mammals. More in particularly, the... Agent: Isaac A. Angres

20080038337 - Smectite dispersibletablets and the preparation thereof: A smectite dispersible tablet and the preparation progress thereof are disclosed, which is a new pharmaceutical formulation of smectite comprising smectite, a filler and a disintegrant. The dispersible tablet is stable in quality, can disintegrate quickly and disperse homogeneously, which is easy in dosage control, convenient in transportation and packaging,... Agent: Straub & Pokotylo

20080038338 - Tetracycline package formulations: The invention provides a rapidly disintegrating and dissolving multilayer tablet comprising at least a tetracycline in a first layer, a buffer in a second layer, and optionally, an inert layer separating the first and second layers. The multilayer tablets of the invention are useful for treating or preventing mucositis, when... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080038341 - Direct compression formulation and process: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and... Agent: Novartis Corporate Intellectual Property

20080038343 - Pharmaceutical composition containing a tetrahydrofolic acid: The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the... Agent: Millen, White, Zelano & Branigan, P.C.

20080038342 - Stable pharmaceutical composition comprising an ace inhibitor: The present invention relates to a stable pharmaceutical composition comprising an ACE inhibitor or a pharmaceutically acceptable salt or derivative thereof. In particular, the invention relates to a pharmaceutical composition, which comprises an ACE inhibitor, or a pharmaceutically acceptable salt or a derivative thereof, and a C16-C28 glyceride. ACE inhibitors... Agent: Wolf Greenfield & Sacks, P.C.

20080038346 - Extended release tablet formulations of flibanserin and method for manufacturing the same: The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of a) flibanserin or a pharmaceutically acceptable derivative thereof as active substance; b) one or more pharmaceutically acceptable pH-dependent polymers; c) one or more pharmaceutically acceptable... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080038347 - Extended release tablet formulations of flibanserin and method for manufacturing the same: The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Cmax lower than 300 ng/mL, preferably lower than... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080038345 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080038344 - Solid pharmaceutical preparation: To provide a sustained-release solid pharmaceutical preparation having a quick-release part and a sustained-release part and stably having an excellent quick releasing characteristic with little pH dependency in an initial dissolution. The present invention relates to that, in a preparation containing a medical ingredient as an effective ingredient, particularly active... Agent: Oliff & Berridge, PLC

20080038348 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080038350 - Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol: The peroral medication for prevention of conception contains as one active ingredient crystalline 17α-cyanomethyl-17β-hydroxyestra-4,9-dien-3-one (dienogest) at a daily dosage equal to or less than 2.0 mg and as another active ingredient 17α-ethinyl estradiol at a daily dosage of less than 0.030 mg, together with one or more pharmaceutically acceptable carriers.... Agent: Striker, Striker & Stenby

20080038349 - Peptide-pna chimera targeting inducible nitric oxide synthetase: Peptide Nucleic Acid (PNA) antisense specific for inducible nitric oxide (iNOS) wherein the PNA compound is composed from nucleic acid sequence targeting iNOS, a peptide ligand which binds to a specific receptor, a positively charge moiety and an hydrophobic moiety. The invention also relates to the use of these compounds... Agent: Pearl Cohen Zedek Latzer, LLP

20080038351 - Flowable carrier matrix: A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter... Agent: Fox Rothschild, LLP

20080038352 - Electroprocessed collagen and tissue engineering: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen... Agent: Beth E. Arnold Foley Hoag LLP

20080038353 - Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs: The present invention is in the field of polymer-based nano-carriers for the solubilization and delivery of hydrophobic drugs, and relates to methods of making said carriers, and to pharmaceutical compositions comprising said carriers. Novel PEO-b-PCL micelles and micelles containing cyclosporine A or analogs thereof are provided as well as a... Agent: Bennett Jones C/o Ms Roseann Caldwell

20080038354 - Active agent eluting matrices with particulates: The present invention is directed to polymeric matrices for the controlled release of a hydrophilic bioactive agent. Generally, the elution control matrix includes a polymeric matrix having a first polymer and a plurality of microparticles that include the hydrophilic bioactive agent. In one embodiment, the matrix includes a polymer comprising... Agent: Kagan Binder, PLLC

20080038355 - Bioadhesive dosage form of steroids: Bioadhesive steroid nanoparticles are used to prepare a rapidly disintegrating solid oral dosage form of steroid. The bioadhesive steroid nanoparticles have a bioadhesive polymer surrounding the steroid nanoparticles and with an average diameter of less than 1000 nm. Hence, the solid oral dosage form, containing the bioadhesive steroid nanoparticles, a... Agent: Occhiuti Rohlicek & Tsao, LLP

20080038358 - Dry powder formulations of antihistamine for nasal administration: Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080038357 - Inhalation powder containing the cgrp antagonist bibn4096 and process for the preparation thereof: The invention relates to an inhalation powder for treating migraine, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I as the active substance base in the form of spherically nanostructured microparticles, and a process for the manufacture thereof.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080038356 - Spray freeze-dried compositions: A process for producing a powder comprises spray freeze-drying an aqueous solution or suspension comprising a pharmaceutical agent, said solution or suspension having a solids content of 20% by weight or more. The spray freeze-dried powder may be administered to a subject via a needleless syringe.... Agent: Bingham Mccutchen LLP

20080038359 - Stable nanoparticle formulations: The invention relates to pharmaceutically stable nanoparticle formulations of poorly soluble drug substances, to the processes for the preparation of such formulations, and to methods of use thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080038360 - Personal care composition: Personal care composition comprising from about 0.1% to about 15% of an emulsifying silicone elastomer; from about 1% to about 90% of an aqueous phase; and from about 0.001% to about 5% of a coated particulate comprising a core material and a coating material, wherein the coated particulate has a... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080038361 - Water-soluble nanoparticles stabilized with multi-functional group ligands and method of preparation thereof: Disclosed are water-soluble nanoparticles. The water-soluble nanoparticles are each surrounded by a multifunctional group ligand including an adhesive region, a cross linking region, and a reactive region. In the water-soluble nanoparticles, the cross-linking region of the multifunctional group ligand is cross-linked with another cross-linking region of a neighboring multifunctional group... Agent: Sheridan Ross PC

20080038362 - Composition for an enteric coating of natural product containing lectin: This invention is accomplished by producing an effective composition for enteric coated medicine of mistletoe extract C) containing lectin and producing an effective composition for enteric coated microcapsule which has lectin as a major ingredient. The problem with oral administration due to unstability in the digestive system was solved and... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080038363 - Aerosol delivery system and uses thereof: A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the... Agent: Wilson Sonsini Goodrich & Rosati

20080038364 - Methods of processing body parts for surgery: Process for a transplantable body part including extracting soluble materials therefrom, contacting the part with ozone, submerging the part in an inert body of liquid, contacting the part with nanoparticles coated with a growth factor or medicinal, and thereafter applying a pressure between 68,000 and 100,000 pounds per square inch... Agent: Marshall A. Burmeister

20080038365 - Trpc6 involved in glomerulonephritis: Focal and segmental glomerulosclerosis (FSGS) is a kidney disorder of unknown etiology and up to 20% of patients on dialysis have this diagnosis. A large family with hereditary FSGS carries a missense mutation in the TRPC6 gene on chromosome 11q, encoding the ion channel protein Transient Receptor Potential Cation Channel... Agent: Banner & Witcoff, Ltd.

20080038366 - Actin regulatory elements for use in plants: The present invention provides polynucleotide molecules isolated from Oryza sativa and Zea mays and useful for expressing transgenes in plants. The present invention also provides expression constructs containing the polynucleotide molecules useful for expressing transgenes in plants. The present invention also provides transgenic plants and seeds containing the polynucleotide molecules... Agent: Sonnenschein Nath & Rosenthal LLP

20080038367 - Nutritional supplement compositions and methods of preparing: The present invention relates to a nutritional supplement composition and methods for preparing. The invention further provides a method for creating a nutrient supplement drink composition comprising the a carrier liquid, a flower distillate, and at least one herbal extract component, and optionally including an additional ingredient selected from the... Agent: Mccarter & English LLP Cityplace I

20080038368 - Fast acting inhibitor of gastric acid secretion: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast... Agent: Henry D. Coleman

20080038369 - Methods and compositions for the treatment of prolactin-receptor related disorders: The present invention provides methods and compositions for the treatment, diagnosis, prevention, or amelioration of one or more symptoms of a prolactin receptor-related condition, including, for example, a cancer such as breast cancer or prostate cancer, by administering a growth hormone-based prolactin receptor antagonist and zinc, or administering a growth... Agent: Bozicevic, Field & Francis LLP

20080038370 - Composition and method for treating the effects of diseases and maladies of the upper digestive tract: The present invention relates to a nutraceutical composition for supporting body structures and functions in the upper digestive tract. The nutraceutical composition contains an effective amount of (a) an antioxidant having gastric proton pump inhibiting effects, (b an acid neutralizer; and (c) an antibacterial agent effective against Helicobacter pylori. This... Agent: Lucas & Mercanti, LLP

20080038371 - Nanoparticle formulations of platinum compounds: Solid Lipid Nanoparticles of platinum compounds, particularly of antitumor platinum complexes are disclosed. The Nanoparticles of the invention are obtained by a process comprising: a) preparing a first microemulsion by mixing a molten lipid, a surfactant, and optionally a co-surfactant and the platinum compound acqueous solution; b) preparing a solution... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080038372 - Artificial physiological salt solution and manufacturing method for same: An artificial physiological salt solution, wherein the active hydrogen reaction value is 0.01 to 1, the pH is 4.0 to 7.9 and the osmotic pressure is 260 mOsm/L to 2560 mOsm/L, as well as a manufacturing method for the same are provided as a novel artificial physiological salt solution, which... Agent: Birch Stewart Kolasch & Birch

20080038373 - Decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, methods for obtaining and using said composition: The invention concerns a decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, comprising as active components eugenol, eugenol acetate, vanillin and carvacrol, characterized in that said active constituents are present in the following percentages by weight: at least about 12% eugenol, at least about 3% eugenol acetate, at least... Agent: Jordan And Hamburg LLP

20080038374 - New use: The present invention relates to the use of a vitamin D compound active in up-regulating the expression and production of hCAP18 in humans for the manufacture of a medicament for treatment of conditions deficient in or benefiting from LL-37. The vitamin D active compound can be used as a medicament... Agent: Birch Stewart Kolasch & Birch

20080038375 - Method and compositions for bath: A bathing product for bathing comprises: a sodium hydrogen carbonate, commonly known as baking soda, being usable for softening the bathing water, removing body odor, revitalizing skin and facilitating enhanced body care or treatment, and a water sanitizing agent, being usable for effectively sanitizing the liquid and cleaning the bath... Agent: Hyun Jong Park Tuchman & Park LLC

20080038376 - Anti-cancer composition and method for using the same: This invention encompasses an expeditious method and compositions that have been found to show selective cytotoxicity against several different cancer cell lines. for treating a wide variety cancer neoplasms that have tumor microenvironments by administering a stand-alone anti-tumor chemotherapeutic composition or administered as an adjunct with chemotherapy and/or radiotherapy with... Agent: Snell & Wilmer L.L.P. (main)

20080038377 - Device for treatment of inflamed tissue: A device having a squeezable hollow member connected to a medication chamber in turn connected to a hollow tube fitted with an absorbent tip. The device may be used to conveniently administer a medication to an inflamed tissue. A method of providing a medication to an inflamed tissue is also... Agent: Michael Best & Friedrich LLP

20080038378 - Pufa polyketide synthase systems and uses thereof: The invention generally relates to polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems isolated from or derived from non-bacterial organisms, to homologues thereof, to isolated nucleic acid molecules and recombinant nucleic acid molecules encoding biologically active domains of such a PUFA PKS system, to genetically modified organisms comprising PUFA PKS... Agent: Sheridan Ross PC

20080038379 - Pufa polyketide synthase systems and uses thereof: The invention generally relates to polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems, to homologues thereof, to isolated nucleic acid molecules and recombinant nucleic acid molecules encoding biologically active domains of such a PUFA PKS system, to genetically modified organisms comprising PUFA PKS systems, to methods of making and using... Agent: Sheridan Ross PC

20080038380 - Acorus gramineus soland extract for preventing and treating ischemic heart disease and pharmaceutical composition and health food containing the same: The present invention relates to an Nelumbinis semen extract having the effect of preventing or treating ischemic heart disease, as well as a pharmaceutical composition and health food for the prevention or treatment of ischemic heart diseases, which contain the Nelumbinis semen extract. The inventive Nelumbinis semen extract and the... Agent: Ipla P.A.

20080038381 - Application of green tea extract and its major components in keloid scar therapy: A composition comprising a green tea extract (GTE) or its major component, (−)-epigallocatechin-3-gallate (EGCG). Also disclosed is a method of using the composition for keloid scar therapy.... Agent: Hogan & Hartson L.L.P.

20080038382 - Extracts of scutellaria for the treatment of sars: The present invention relates to pharmaceutical compositions having antiviral activity against Coronavirus, and more particularly against those viruses responsible for Severe Acute Respiratory Syndrome (SARS). In a preferred embodiment it comprises a total standardized extract of a Scutellariae spp.... Agent: Dickinson Wright PLLC

20080038383 - Pesticidal compositions containing rosemary oil and wintergreen oil: Pesticidal compositions containing rosemary oil and/or wintergreen oil and methods for using same are disclosed.... Agent: Nixon & Vanderhye, PC

20080038384 - Formulation to aid in management of irritable bowel syndrome with urgency symptoms.: A formulation designed to help sufferers of Irritable Bowel Syndrome who are prone to urgency symptoms. The formulation contains herbs, calcium carbonate, and food ingredients and the combination aids in management of the condition.... Agent: Howard Sachs Dwd Consumer Products, Inc.

20080038385 - Therapeutic uses of an anti-cancer composition derived from rice bran: A nutritional fiber derived from stabilized rice bran is described, as well as the use thereof for the prevention and treatment of several GI disorders, bowel disorders, as a laxative, in weight loss diets, as a therapeutic diet for reducing cholesterol and blood glucose levels, for dissolving and preventing kidney... Agent: Townsend And Townsend And Crew, LLP

20080038386 - Use of a liquid cooling sensate to provide a pungent, warming or tingling sensate composition: The present invention is directed to a sensate composition consisting of a liquid cooling composition, and at least one warming, tingling, or pungent sensate ingredient of either synthetic or natural origin which provides enhanced warming, tingling, or pungent properties. The liquid cooling sensate of the invention is a eutectic mixture... Agent: Qaroma Inc. Subsidiary Of Chemicals Incorporated

20080038387 - Therapy of estrogen-associated disorders: A method for the treatment, prophylaxis, amelioration or prevention of disorders associated with abnormally high activity of steroidal estrogens, which includes administering to a human subject a composition comprising an isoflavone-containing extract of clover or chick peas, said extract comprising primarily biochanin, or a ration of biochanin to one or... Agent: Nath & Associates

20080038388 - Method of obtaining a firming active principle, active principle thus obtained and uses thereof: The invention relates to a method of obtaining a firming active principle resulting from the solubilisation of Cucurbita pepo seed meal treated by means of enzymatic hydrolysis. The invention also relates to the active principle thus obtained and to the uses thereof in cosmetics.... Agent: Young & Thompson

20080038389 - Appetite-suppressing compositions and methods: The invention relates to appetite-suppressing compositions obtained from botanical sources. More specifically, the invention relates to appetite-suppressing compositions comprising an extract product of an Asclepias plant, methods of making an appetite-suppressing composition, and methods of suppressing an appetite.... Agent: Marshall, Gerstein & Borun LLP

20080038390 - Alkaloid compounds and their use as anti-malarial drugs: e

20080038391 - Stable and bioavailable compositions of isomers of carotenoids for skin and hair: The present invention relates to a method of manufacturing a stable composition enriched in cis-lycopene (z-isomers) by prolonged heating in solvents of tomatoes, parts of tomatoes, derivative thereof or tomato extracts in solvents.... Agent: Ladas & Parry

20080031814 - Non-allergenic ingredients and food products: The present invention relates to a non-allergenic food product including an amino acid fraction including at least one component selected from one or both of amino acids and peptides having a degree of polymerization of 7 or less, and a lipid fraction including at least one fatty acid selected from... Agent: Banner & Witcoff, Ltd.

20080031817 - Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents: Though copper is elevated in the tumor tissue and plasma of patients with various malignancies, the molecular targets for copper binding agents in angiogenesis and tumor progression remain poorly understood. It is disclosed that one anti-angiogenic target for the copper binding agent tetrathiomolybdate is intracellular CuZn-superoxide dismutase (SOD1). A second... Agent: Mckenna Long & Aldridge LLP

20080031828 - Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol: The present invention relates to the use of tiotropium salts in combination with salts of salmeterol for the manufacture of a medicament for the treatment of dyspnea.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080031831 - Oral anti-calculus compositions and methods of use thereof: The present invention provides anticalculus oral compositions containing a plant oil mixture comprising a major oil constituent and a minor oil constituent in a proportion of at least 10/1 respectively. The major oil constituent comprises an edible vegetable oil and the minor oil consitutent comprises emulsifying oil, flavoring oil, antiseptic... Agent: Law Offices Of Khalilian Sira, LLC

20080031832 - Surface-doped particles of ti02 or zno and their use: A particle of TiO2 or ZnO which has been doped with one or more other elements such that the concentration of dopant in the surface of the particle is greater than that at the core of the particle, and compositions containing such particles for use as sunscreens or in veterinary,... Agent: Wolf Greenfield & Sacks, P.C.

20080031838 - Tracing hand cleaner: Among other things, a tracer material that is or has been part of a skin cleaner composition is detected, and based on detecting the tracer material, at least one characteristic of the cleaner composition is determined.... Agent: Fish & Richardson PC

20080031844 - Compositions to reduce animal waste malodors: Methods and compositions for reducing animal waste malodor using agents and cross-adapting agents are described.... Agent: Woodcock Washburn LLP

20080031850 - Tissue regeneration method: The invention relates to the use of haematopoietic growth factors, in particular erythropoietin (EPO) and thrombopoietin (TPO), or derivatives, analogues or parts thereof, for promoting structural tissue regeneration.... Agent: Clark & Elbing LLP

20080031860 - Compositions comprising pantothenic acid or derivatives thereof and their use for stimulating appetite: The invention relates to the field of food compositions and their use. In particular compositions comprising at least 15 En % protein and pantothenic acid, or equivalents thereof, are provided, which are suitable for stimulating appetite.... Agent: The Webb Law Firm, P.C.

20080031868 - Human lysozyme medicine, its manufacturing method and application thereof: The present invention relates to biomedicine, in particular, relates to human lysozyme medicine in the form of aerosol, which contains 1,500-3,000,00 U/ml human lysozyme, and its manufacturing method. In a certain embodiment of the invention, the medicine consist of recombinant human lysozyme which activity is at the range of 15,000... Agent: Eric Chan

20080031869 - Pain relief composition: The pain relief composition is a combination of dietary and nutritional supplements that has been found effective for the relief of pain arising from a wide variety of diseases and injuries, regardless of severity or chronicity. The composition is formulated for oral administration, such as a tablet, soft gel capsule,... Agent: Litman Law Offices, Ltd.

20080031811 - Method for preparing radioactive film: The present invention relates to a method for preparing a radioactive film for local radioactive treatment. More particularly, the present invention relates to a method for preparing a radioactive film comprising the steps of; dissolving 0.1˜14.5 weight % of a stable nuclide and 13˜32.5 weight % of a film-forming base... Agent: Lucas & Mercanti, LLP

20080031812 - Redox-stable, non-phosphorylated cyclic peptide inhibitors of sh2 domain binding to target protein, conjugates, thereof, compositions and methods of synthesis and use: in which (i) aa1 is Adi and aa4 is Glu or (ii) each of aa1 and aa4 is Adi, L is sulfur, sulfoxide, oxygen or methylene, which compound (and its conjugates) bind to an SH2 domain in a protein comprising an SH2 domain, is non-phosphorylated, is redox-stable in vivo, is... Agent: Leydig, Voit & Mayer, Ltd.

20080031813 - Targeted combination immunotherapy of cancer and infectious diseases: The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present... Agent: Faegre & Benson LLP Patent Docketing

20080031816 - Methods and compositions for identifying biomarkers: The present invention provides methods and compositions for the identification and validation of biomarkers. The methods and compositions of the invention include the use of exogenous molecules specifically designed and chosen to be associated with a particular disease or biological process. Biomarkers identified and used according to the invention can... Agent: Morgan, Lewis & Bockius LLP (sf)

20080031815 - Pet imaging of vascular endothelial growth factor receptor (vegfr), compositions for vegf cancer imaging, and methods of vegf cancer imaging: Briefly described, embodiments of this disclosure include polypeptides, in particular a labeled VEGF protein, kits for imaging, methods for imaging tissue, methods of diagnosing the presence in a tissue of one or more of precancerous cells, cancerous cells, tumor cells, and cells related to ischemic or hypoxic related diseases, methods... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20080031819 - Compositions and methods that enhance articular cartilage repair: In general, this invention relates to compositions and methods useful in enhancing articular cartilage repair by providing for the sustained release of growth factors to articular cartilage cells to induce cell proliferation and extracellular matrix synthesis.... Agent: Clark & Elbing LLP

20080031822 - Methods of modeling migraine pain and identifying candidate compounds for the treatment of migraine: The present invention features animal models of migraine pain that can be used in a variety of ways, e.g., to identify compounds that reduce migraine pain or other migraine symptoms, to investigate behavioral changes correlated with the development and maintenance of a migraine-like state, and to better understand the mechanisms... Agent: Clark & Elbing LLP

20080031820 - Swine multipotent adult progenitor cells: The present invention provides swine cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple cell types. Also provided are methods of isolation and culture, as well as uses for the cells, such as xenogeneic transplantation and/or tissue repair.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080031821 - Use of core 2 glcnac transferase inhibitors in treating inflammation: This invention provides compounds and methods for treating inflammation. The compounds modulate the core 2 oligosaccharide-mediated binding of inflammatory cells, such as neutrophils, to endothelial cells and other myeloid cells. Significantly, the of the invention methods block inflammation without affecting lymphocyte trafficking. In some embodiments, the compounds inhibit the activity... Agent: Townsend And Townsend And Crew, LLP

20080031818 - Use of modulators of a novel form of muscle selective calcineurin interacting protein (mcip-1-38) as a treatment for cardiovascular diseases: The present invention describes a novel form of the MCIP protein, a 38 kDa version (MCIP-1-38) that predominates in the human heart, the upregulation of which is strongly suggested for the treatment or prevention of heart disease. The present invention provides for methods of treating and preventing cardiovascular diseases, in... Agent: Fulbright & Jaworski L.L.P.

20080031823 - Agents for therapy efficacy monitoring and deep tissue imaging: Compounds and methods related to NIR molecular imaging, in-vitro and in-vivo functional imaging, therapy/efficacy monitoring, and cancer and metastatic activity imaging. Compounds and methods demonstrated pertain to the field of peripheral benzodiazepine receptor imaging, metabolic imaging, cellular respiration imaging, cellular proliferation imaging as targeted agents that incorporate signaling agents.... Agent: Stites & Harbison PLLC

20080031824 - Swellable particles for drug delivery: Swellable particles for delivery of a drug or other working agent to the pulmonary system are provided. The swellable particles include a dehydrated (dry) aerodynamic particle diameter of 5 μm or less to enable delivery to the respiratory tract, such as for example to the tracheo-bronchial airways of the upper... Agent: Mr. Edward J. Timmer

20080031826 - Devices containing lipid emulsions: The present invention relates to compositions and methods for the storage and consumption of a lipid emulsion. In particular, the present invention relates to the storage of an omega-3 lipid emulsion for consumption in a container under non-oxidizing conditions.... Agent: Casimir Jones, S.c.

20080031827 - Injectables in foam. new pharmaceutical applications: The placing of a drug that is suitable for parenteral administration on bubbles formed with sterile gases produces an exponential increase in its active surface area with a decrease in the diameter of the bubble, modifies the kinetics of its distribution and, thanks to its micronisation, increases its therapeutic effect.... Agent: Klauber & Jackson

20080031825 - Pharmaceutical compositions comprising effervescent agents and fenofibrate: A pharmaceutical composition comprising at least one effervescent agent and a fibrate and a process for making such composition. The fibrate is fenofibrate and the effervescent agent are in a dosage form. The dosage form increases dissolution and absorption of fenofibrate in biological conditions where the form contacts acidic gastric... Agent: Robert Deberardine Abbott Laboratories

20080031829 - Cosmetic composition comprising at least one polysaccharide of lambda-carrageenan type in aerosol form, method for the cosmetic treatment of keratinous fibers, and product comprising the composition: Disclosed herein is a cosmetic composition for the treatment of keratinous fibers, for example, human keratinous fibers, such as the hair, in the form of an aerosol comprising at least one polysaccharide of lambda-carrageenan type and carbon dioxide as propellant. Also disclosed herein is a cosmetic treatment method for keratinous... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080031830 - Dental composition containing an epoxy functional carbosilane compound: The present invention relates to a dental composition comprising least one carbosilane compound comprising at least one Si-Aryl bond, at least one silicon atom, no Si—Oxygen bond, at least one aliphatic epoxy moiety, wherein said carbosilane compound has no glycidyl ether moieties; and an initiator, optionally filler and optionally additive... Agent: 3m Innovative Properties Company

20080031833 - Combined energy and topical composition application for regulating the condition of mammalian skin: Method for regulating the condition of mammalian skin comprising the steps of applying a first personal care composition to an area of skin where regulation is desired, wherein the first personal care composition comprises at least one skin care active selected from the group consisting of niacinamide, salicylic acid, peptides,... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080031834 - Cosmetic compositions: A cosmetic composition comprising at least one cyclized dimethicone solvated or dispersed in a cosmetically acceptable carrier.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20080031835 - Antiinflammatory and analgesic preparation for external use: It is intended to provide an antiinflammatory and analgesic preparation for external use whereby side effects of a nonsteroidal antiinflammatory and analgesic drug on the skin can be regulated, the nonsteroidal antiinflammatory and analgesic drug can be prevented from degeneration with time due to a dibenzoylmethane derivative contained as an... Agent: Licata & Tyrrell P.C.

20080031837 - Block polymers and their process of preparation: Disclosed herein are novel block polymers comprising at least one first block and at least one second block, wherein the at least one first block comprises at least one acrylate monomer of formula CH2═CH—COOR2 wherein R2 is chosen from C4 to C12 cycloalkyl groups and at least one methacrylate monomer... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080031836 - Crosslinked nail varnish film: The invention relates to a flexible article which is used to make up and/or care for nails and/or false nails, comprising: at least one adhesive layer which is used to fix the article to the nail, and at least one cross-linked film.... Agent: Oliff & Berridge, PLC

20080031841 - Cosmetic composition comprising at least one lambda-carrageenan polysaccharide in combination with at least one specific polyol, and process for cosmetic treatment of keratin fibers with the composition, and use of the composition for hair care: The present disclosure relates to a cosmetic composition for the treatment of keratin fibers, for instance human keratin fibers such as the hair, comprising at least one lambda-carrageenan polysaccharide, at least one polyol containing in its structure at least 3 hydroxyl groups, other than carrageenans, and at least one specific... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080031842 - Personal cleansing compositions: The present invention is a lathering cleansing composition comprising an alkyl ethoxylated polymer, at least one lathering surfactant, an acrylate cross linked copolymer and a particulate material and a lathering surfactant. These compositions provide good lathering and are readily rinsed. The particulate materials enhance cleansing and exfoliation or provide conditioning... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080031843 - Soap-free, self-foaming shaving gel comprising an n-acylsarcosine: c) at least one mineral or organic base in an amount sufficient to dissolve the N-acylsarcosine and produce a pH of 4 to 8; d) at least one anionic surfactant; e) at least one non-ionic surfactant; and f) at least one self-foaming agent.... Agent: Buchanan, Ingersoll & Rooney PC

20080031839 - Agent for prermanent hair processing:

20080031840 - Water-based olefin-graft polymer system for multifunctional cosmetic applications: A polymer emulsion for use in a cosmetic composition includes an olefin copolymer; a copolymer of an acidic monomer to include acrylic acid, methacrylic acid or other unsaturated, carboxyl containing monomer; optionally, at least one stabilizing emulsifier; optionally, a resin selected from a group consisting of an acrylic resin and... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080031845 - Personal care compositions that deposit hydrophilic benefit agents: A personal care composition comprising a hydrophilic liquid, a structurant for said hydrophilic liquid, a surface active, a lipid, and an aqueous phase; wherein said lipid, said hydrophilic liquid, said structurant, and said surface active form a lipid phase; wherein said hydrophilic liquid, said structurant, and said surface active are... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080031846 - Compositions with enhanced antimicrobial efficacy against acanthamoebae: A method for cleaning or disinfecting contact lenses comprising providing an ophthalmic composition comprising a quaternary polymer and a primary antimicrobial agent with the proviso that the quaternary polymer is not a cationic cellulosic polymer and is distinct from, and mutually exclusive of, the primary antimicrobial agent.... Agent: John E. Thomas Law Department

20080031847 - Methods and kits for treating lacerations and puncture wounds using inverse thermosensitive polymers: In certain embodiments, the present invention relates to methods and kits for treating wounds, comprising the step of introducing into said wound a composition comprising at least one optionally purified inverse thermosensitive polymer, wherein said at least one optionally purified inverse thermosensitive polymer forms a gel in said wound, thereby... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080031848 - Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds:

20080031849 - Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors: The invention concerns vaccines comprising as an active principle an immunogen which is a cytokinetic factor or a cell regulating factor particularly transcriptional or another type of factor with immunosuppressive/apoptotic/angiogenic properties abnormally released in the extracellular (stromal) environment by cancer or stromal cells of malignant tumors, and a pharmaceutically acceptable... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080031851 - Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus: The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is... Agent: Fish & Richardson P.C.

20080031852 - Pyrro[1,2-b]pyridazinone compounds: The invention is directed to pyrro[1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20080031853 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20080031854 - Thiolated macromolecules and methods of making and using thereof: Described herein are thiolated macromolecules and methods of making and using thereof.... Agent: Heller Ehrman LLP

20080031855 - Anticancer agent containing minus-strand rna virus: Minus-strand RNA viruses were found to have an effective tumor-suppressive effect even when they did not carry a therapeutically effective gene. The present invention provides anticancer agents comprising a minus-strand RNA virus. Furthermore, the present invention provides methods for producing the anticancer agents, which comprise the step of mixing a... Agent: Clark & Elbing LLP

20080031856 - Solenopsis invicta virus: Unique Solenopsis invicta viruses (SINV) have been identified and their genome sequenced. Oligonucleotide primers have been developed using the isolated nucleic acid sequences of the SINV. The viruses are used as a biocontrol agent for control of fire ants.... Agent: Usda, Ars, Ott

20080031857 - Cardiomyocyte differentiation: The present invention provides a method of enhancing the efficiency of differentiation of hES cells into cardiomyocytes which method comprises incubating the cells under serum free conditions. The method typically includes providing cells that induce cardiomyocyte differentiation by cell to cell contact. Differentiation to cardiomyocytes can, occur via two routes,... Agent: Scully Scott Murphy & Presser, PC

20080031858 - Cell-matrix microspheres, methods for preparation and applications: A method has been developed to produce stable cell-matrix microspheres with up to 100% encapsulation efficiency and high cell viability, using matrix or biomaterial systems with poor shape and mechanical stability for applications including cell therapeutics via microinjection or surgical implantation, 3D culture for in vitro expansion without repeated cell... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080031859 - Central nervous system neural progenitor cell which induces synapse-forming neurons in the spinal cord: The present invention provides central nervous system neural progenitor cells which can induce neurons with synapse forming ability, oligodendrocytes, astrocytes and the like when transplanted into an injured or disabled spinal cord, a method for preparing said central nervous system neural progenitor cells, a method for screening promoters or inhibitors... Agent: Foley And Lardner LLP Suite 500

20080031861 - Dietary supplements containing natural ingredients: The invention provides a dietary supplement comprising at least one flavonoid source and an enzyme, that is effective for inhibiting in vivo platelet activity and LDL cholesterol oxidation in a mammal at a dosage of about 30 mg/Kg or less. The supplement may contain flavonoid sources found in grape seed... Agent: Fish & Richardson P.C.

20080031862 - Mitochondria-targeted antioxidants: The present invention relates to a pharmaceutical or veterinary or nutritional or personal care composition comprising coenzyme Q10 (CoQ10), reduced CoQ10, or mixtures thereof and oxygenated dibenzo-α-pyrone or an amino acyl ester thereof. The composition of the present invention is able to support and/or provide therapy to individuals at risk... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20080031863 - Method of preparation and use of fibrinolytic enzymes in the treatment of disease: This invention relates generally to a method of preparation of a phyto-percolate having enzymatic, specifically fibrinolytic, activity in the body of mammals, including humans. The phyto-percolate is derived from fresh water mixture including algae that produces an enzyme having proteolytic activity. The invention further relates to the use off the... Agent: Brown, Rudnick, Berlack & Israels, LLP.

20080031864 - Peg-urate oxidase conjugates and use thereof: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080031866 - Method for modulating the pharmacokinetics and metabolism of a therapeutic agent: This invention is a method for enhancing the activity of a therapeutic agent comprising the administration of the agent in combination with an enzyme, whereby a metabolic pathway of the therapeutic agent is counteracted and the agent's pharmacokinetics and metabolism are modulated.... Agent: Philip S. Johnson Johnson & Johnson

20080031865 - Product and process for liquefaction of mucus or sputum: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.... Agent: Sheridan Ross PC

20080031867 - Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, are disclosed. Methods of treatment using the compositions are also disclosed. The material to... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080031872 - Hiv immunogenic composition and method of administration: A method of treatment of HIV by inducing an immune response that includes a robust mucosal immune response. Parenteral administration of an immunogenic composition into the intestinal wall brings the composition into contact with the Peyer's patches of the gut-associated lymphoid system. Administration of multiple immunogenic compositions may track with... Agent: Williams Mullen

20080031871 - Memory and learning impairments associated with disruption of ephrin receptor a6 (epha6) gene: The present application is a continuation-in-part under 37 C.F.R. 1.53(b) of pending prior international application PCT/US2007/61927 filed on Feb. 9, 2007, which claims priority to provisional application No. 60/774,895 filed on Feb. 17, 2006, now abandoned, the entire disclosures of which are hereby expressly incorporated by reference in their entirety.... Agent: Ginger R. Dreger, Esq. Heller Ehrman, LLP

20080031870 - Method of proliferation in neurogenic regions: Novel methods for the use of modulators to modulate an activity of a neural stem cell or a neural progenitor cell in vivo or in vitro are provided. The disclosure provides novel methods for the treatment of neurological diseases and disorders.... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris,

20080031873 - Humanized monoclonal antibody 31.1 as an anticancer agent: The present invention is directed to a CHO cell expression system for high level expression of a chimeric 31.1 monoclonal antibody specific for a human carcinoma-associated protein antigen. The present invention also provides a pharmaceutical composition comprising chimeric 31.1 monoclonal antibody derived from the CHO cells of the invention for... Agent: Baker Botts L.L.P.

20080031875 - Treatment method: The present invention relates to a method for the treating an LFA-1 mediated disorder or a TNF-α mediated disorder by administering effective amounts of an LFA-1 antagonist and a TNF-α antagonist.... Agent: Genentech, Inc.

20080031874 - Treatment of endotoxemia using endotoxin neutralizing agents: Methods and compositions for selecting a patient suffering from endotoxemia for treatment with an endotoxin neutralizing agent are disclosed comprising: (a) determining the level of endotoxin in the patient's blood; and (b) comparing the endotoxin level in the patient's blood to a predetermined threshold endotoxin level to determine if the... Agent: Moore Patents

20080031876 - Ctla4 molecules and il4-binding molecules and uses thereof: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments... Agent: Mandel & Adriano

20080031877 - Purification of bacterial antigens: Presented are methods of isolation of pili and pilus-like structures from Gram-positive bacteria including Streptococcus pneumoniae and compositions that include such isolated pili. These compositions are useful as immunogenic compositions for the production of antibodies and immunostimulation. Also presented are methods of inhibiting Streptococcus pneumoniae, and methods of identifying inhibitors... Agent: Fish & Richardson P.C.

20080031878 - Polypeptides for the diagnosis and therapy of leishamaniasis: The present invention provides compounds and methods for the detection of anti-leishmanial antibodies in individuals suspected of infection with the protozoan parasite of the genus Leishmania, where the infectious agent is an Indian strain and similar or closely related to Indian Leishmania strains. The compounds provided include polypeptides as shown... Agent: Birch Stewart Kolasch & Birch

20080031879 - Pharmaceutical composition containing inhibitors of interferon-gamma: The present invention provides compositions and methods for promoting the healing of wounds or fibrotic disorders with reduced scarring, comprising inhibitors and inhibiting IFN-γ, together with compositions and methods for promoting the healing of chronic wounds, comprising stimulating and stimulators of IFN-γ.... Agent: Nixon & Vanderhye, PC

20080031880 - Use of erbb receptor ligands in treating diabetes: The invention provides methods for treating pancreatic dysfunction, particularly diabetes, in mammals using ErbB receptor ligands, such as heregulin, betacellulin, and EGF. Methods of treating such conditions using anti-ErbB receptor agonist antibodies are further provided. The methods of the invention may be performed by direct administration of such therapeutically useful... Agent: Genentech, Inc.

20080031881 - Medicament for treating cancer: A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.... Agent: Birch Stewart Kolasch & Birch

20080031882 - Methods of modulating il-22 and il-17: The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one... Agent: Wyeth/finnegan Henderson, LLP

20080031883 - Condition-dependent, multiple target delivery system: A condition-dependent, multiple target delivery system providing multifunctional, stimuli-sensitive pharmaceutical carriers is disclosed. The delivery system simultaneously carries on its surface various active moieties. The system is multifunctional and possesses the ability to switch on and switch off certain functions when necessary, for example, under the action of local stimuli... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20080031884 - Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases: A composition for treating, reducing, ameliorating, or alleviating a back-of-the-eye condition or disorder that has an etiology in inflammation comprises a dissociated glucocorticoid receptor agonist (“DIGRA”). The compositions also can include other anti-inflamatory agents, anti-angiogenic agents, or combinations thereof. The composition can be formulated for topical application, injection, or implantation.... Agent: Bausch & Lomb Incorporated

20080031885 - Use of goat serum for veterinary treatment: Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses.... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20080031886 - Viruses for the treatment of cellular proliferative disorders: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus,... Agent: Fish & Richardson P.C.

20080031887 - Conjugates for inducing targeted immune responses and methods of making and using same: Disclosed herein are methods of producing conjugates that include Toll-like receptor (TLR) ligands and targeting molecules that are effective in inducing an immune response. Also disclosed are methods of using such conjugate to treat a disease, such as cancer, infectious diseases and autoimmune diseases.... Agent: Dunlap Codding & Rogers, P.C.

20080031888 - Tumor antigens: Tumor antigen peptides that induce CTL from peripheral blood mononuclear cells of a patient with prostate cancer in an HLA-A2-restricted or an HLA-A24-restricted manner were identified based on the amino acid sequences of PSA, PSM, and PSCA, which are proteins known as markers of prostate cancer. Also disclosed is a... Agent: Kilyk & Bowersox, P.l.l.c.

20080031889 - Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Drinker Biddle & Reath (dc)

20080031890 - Method of inducing neutralizing antibodies to human immunodeficiency virus: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.... Agent: Nixon & Vanderhye, PC

20080031891 - Compositions and methods for reducing or preventing pain in a subject: Described herein are compositions derived from natural products useful in reducing or preventing pain in a subject and methods of use thereof.... Agent: Gardner Groff Greenwald & Villanueva. PC

20080031892 - Immune modulating compounds from fungi: The present invention relates to compositions comprising polypeptides and polysaccharides. The compositions are in general immune modulating. The invention also discloses methods of producing these compositions using filamentous fungi cultivated in liquid medium. The compositions are useful for example in the treatment of immune compromised conditions.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080031893 - Acacia based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on Acacia fractions, compounds, and extracts.... Agent: Mcdermott Will & Emery LLP

20080031894 - Beta acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on beta acids, commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080031895 - Influenza virus-like particle (vlp) compositions: Influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these VLPs as well as methods of making and using these VLPs.... Agent: Robins & Pasternak

20080031896 - Coccidiosis vaccines: Described are coccidia strains and microbiological cultures comprising such strains. The coccidia strains are selected for tolerance to one group of coccidiostatic drugs, sensitivity to a second group of coccidiostatic drugs, and decreased proliferative capacity. Also described are compositions and vaccines based on such coccidia strain.... Agent: Trask Britt

20080031897 - Prevention of allergy in children: The present invention relates to a use of bacterial superantigens in the manufacture of a pharmaceutical composition for mucous membrane administration for the prevention of inflammatory disorders in newborn infants, such pharmaceutical compositions, as well as method for prevention of inflammatory disorders.... Agent: Gauthier & Connors, LLP

20080031898 - Compositions and methods to increase the effect of a neurotoxin treatment: The present invention discloses compositions and methods for enhancing the effect (e.g., duration) of a neurotoxin treatment. The compositions herein include neurotoxins and neuron growth inhibitors. Such compositions are administered locally to treat or prevent conditions, such as dermatological conditions, urological conditions, thyroid conditions, optical conditions, and neurological conditions.... Agent: Wilson Sonsini Goodrich & Rosati

20080031900 - Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells: The present invention includes compositions and methods for making a pharmaceutically effective amount of one or more dendritic cells matured by exposure to IFNα loaded with cancer antigens from cells that are heat shocked and subsequently killed, wherein the one or more IFNα dendritic cells are under conditions to present... Agent: Chalker Flores, LLP

20080031899 - Nanoparticles for immunotherapy: Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics.... Agent: Dardi & Associates, PLLC

20080031902 - 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof: wherein: R1 is hydrogen, cyano, halogen, R8, formyl, —C(O)R8, —C(O)OR8, —C(O)NR9R10, or —C(S)NH2; R2 is R2 or —S(O)mR11; R3 is methyl, ethyl or C1-C4 haloalkyl; R4, R5 and R7 are independently hydrogen, halogen, alkyl, haloalkyl, cyano or nitro; R6 is halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy, cyano, nitro, —C(O)R12, —S(O)nR12 or... Agent: Judy Jarecki-black, Ph.d.,j.d

20080031903 - Method of treating ocular infections: Provided herein are methods of preventing or treating ocular viral, fungal, protozoa or bacterial infections. The method comprises administering ocular doses of a binding agent reactive against a virus, fungus, protozoa or bacteria, which, in one embodiment, is a pooled, human immunoglobulin preparation, such as, without limitation, those suitable for... Agent: Jesse A. Hirshman, Esq.

20080031901 - Sustained release monoeximic formulations of opioid and nonopioid analgesics: The present invention relates to monoeximic solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.... Agent: Dykema Gossett PLLC

20080031904 - Combination consisting of a magnesium preparation having a prolonged release and of another active substance, and use thereof in the fields of cosmetics, therapeutics and/or nutrition: The present invention relates to a combination useful in the fields of cosmetics, therapeutics and/or nutrition, for acting in particular against stress conditions, characterised in that it consists of (α) a sustained release preparation (I) comprising, in association with a physiologically acceptable excipient, a mixture of: (A) magnesium derived from... Agent: Ostrolenk Faber Gerb & Soffen

20080031905 - Method for treatment of burns: A method of treating minor burns includes applying a water-based wax emulsion to the area of the burn. When the emulsion dries, it forms a thin, protective film over the burn. Application of the emulsion has been found to provide temporary and immediate relief of pain and/or itching. The protective... Agent: William H. Eilberg

20080031907 - Cosmetic and pharmaceutical foam: The invention relates to uses of an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent as a flame retardant or flame resistant foam. The hydrophobic solvent is preferably mineral oil; medium chain triglycerides; isopropyl myristearate... Agent: Wilmerhale/boston

20080031906 - Cosmetic composition and method for producing the same: An emulsion and dispersion system exhibiting excellent stability against heat and excellent stability over a long period time in interfaces between functional oily bases and water, or between functional granules as solid particles and water, etc., a cosmetic composition containing an emulsifying dispersant which is capable of performing emulsification and... Agent: Mcginn Intellectual Property Law Group, PLLC

20080031910 - Delivery system for an oral care substance: A tooth whitening substance formed into a thin layer is provided. The tooth whitening substance includes a polyox resin and a tooth whitening active. The polyox resin adheres the thin layer to a plurality of teeth for a sufficient time to allow the tooth whitening active to act upon the... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080031909 - Encapsulated cosmetic materials: Cosmetic materials, e.g., sunscreen agents are encapsulated by means of a compound of the formula (I) where X is O or NR5; EWG is an electron-withdrawing group; R1, R2, R3, R5 are equal to an H, alykl, cycloalkyl, aryl, or heterocyclic group; or R1, R2 and R5 or R1, R2... Agent: Nixon & Vanderhye, PC

20080031908 - Oily cosmetic composition in aerosol form: Aerosol product containing an oily composition containing at least one oil, and at least one hydrocarbon compound having a melting point greater than or equal to 30° C., the compound being in the form of solid particles and one or more propellants. The hydrocarbon compound can notably be a paraffin... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080031911 - Inhibiting smad signaling promotes neuron regeneration: Regeneration of a lesioned CNS axon of a mature neuron, determined to be subject to regeneration inhibition by Smad2/3 signaling, is promoted by contacting the neuron with an inhibitor of Smad2/3 signaling sufficient to promote regeneration of the axon.... Agent: Richard Aron Osman

20080031912 - Method for controlling cell migration on a surface: A method for directing or inhibiting cell migration on a two- or three-dimensional surface by contacting the surface with ephrin, peptide fragments derived from full-length ephrin, or synthetic peptide/small molecule agonists of Eph receptor tyrosine kinases. These surfaces include implantable, biocompatible devices which need to be completely or partially cell-free.... Agent: Knobbe Martens Olson & Bear LLP

20080031913 - Method for manufacturing biomedical filler material rich-contained with growth factor: A method for manufacturing at least one kind of biomedical filler materials rich-contained with at least one growth factor is disclosed, wherein at least one dry powder composed of the growth factor is provided to cover the surface of a plurality of filler materials via a physical electro-adsorption action. The... Agent: Rosenberg, Klein & Lee

20080031914 - Flowable biomaterial composition: A putty form biomaterial composition made of a collagen scaffold and ceramic granule having improved flowable yet cohesive characteristics through the addition of, either individually or in some combination, polyhydroxy compounds, a liquid polyhydroxy compound ester, a liquid solution of solid polyhydroxy compound, a liquid solution of solid polyhydroxy compound... Agent: Fox Rothschild, LLP

20080031919 - Adding microscopic porosity to the surface of a microcoil to be used for medical implantation: A vasoocclusive microcoil for therapeutic treatment of a patient's vasculature includes a surface with a plurality of voids or pores therein, and a therapeutic or bioactive material disposed within the plurality of voids or pores. The therapeutic or bioactive material within the plurality of voids or pores operates to accelerate... Agent: Fulwider Patton LLP

20080031918 - Barriers for polymeric coatings: A barrier adapted to be positioned between a first surface provided in the form of a polymeric, bioactive agent-containing coating upon a medical device, and a second surface provided by another material positioned in apposition, and preferably moveable apposition, to the first surface. The barrier, as provided by block copolymers... Agent: Surmodics, Inc.

20080031920 - Bone cell delivery device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20080031921 - Bone cell delivery device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20080031917 - Bone graft substitute composition: Bone graft substitute compositions and methods of making the compositions are disclosed. In some embodiments, a method of making a composition includes contacting a mixing solution with a first mixture having calcium sulfate hemihydrate and a plasticizing material to form a second mixture; waiting a predetermined period of time after... Agent: Alston & Bird LLP

20080031915 - Cartilage and bone repair composition: The invention relates to a cartilage and bone repair composition comprising a group of human mesenchymal stem cells that are differentiated to the chondro-osteogenic lineage, by means of the amplification thereof with human serum and a transforming growth factor-beta 1 with a molecular domain for binding to collagen I (TGF-β1-DUC)... Agent: Knobbe Martens Olson & Bear LLP

20080031916 - Dendrimer cross-linked collagen: Dendrimer-crosslinked collagen is provided which is particularly suitable for use as a tissue engineering scaffold. The dendrimer-crosslinked collagen can also incorporate biomolecules to enhance its utility as a tissue engineering scaffold.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080031922 - Delivery system: The present invention relates to a delivery system comprising a core and a membrane encasing said core, wherein said core and mem-brane consist essentially of an elastomer composition and said core comprises at least one therapeutically active agent. The delivery system is characterized in that the membrane comprises at least... Agent: James C. Lydon

20080031923 - Biologic replacement for fibrin clot: The invention provides methods and devices for repairing a ruptured ligament, meniscus, cartilage, tendon, and bone. Methods and products for delivering nucleic acids to damaged tissue are also disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20080031924 - Therapeutic device for delivering controlled air stream flow and/or photodynamic light therapy: A therapeutic device for treating and preventing dermatological diseases and conditions, includes a housing comprising a head portion having an opening through which light energy exits the device and a handle; a light generating assembly adapted to generate and direct a preselected type of light energy to the skin; and... Agent: Watov & Kipnes P.C.

20080031925 - Compositions and methods to lower glycohemoglobin levels: The invention provides for a diet that significantly reduces the glycohemoglobin levels in individuals with type 2 diabetes. A diet plan can be provided to an individual in the form of cards and/or pages with an appropriate meal plan, food items and/or pre-packaged meals, or in an electronic medium for... Agent: Dinesh Agarwal, P.C.

20080031926 - Reversible inhibition of sperm receptor synthesis for contraception: Methods and pharmaceutical compositions are disclosed for reversibly inhibiting sperm receptor activity in animals. Nicarbazin, its derivatives and modifications which retain pharmacological activity are shown to inhibit activity of zona pellucida proteins and concomitant synthesis and/or assembly of the sperm receptor on the oocyte surface necessary for fertilization. Nicarbazin is... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20080031928 - No laxation bulking system: A no-laxation bulking system and a method for preparation of same is disclosed. Gelatin and pectin are combined to fro a dry-blended mixture. A second set of ingredients comprising modified polydextrose and erithritol is then blended to form a first liquid mixture. A second liquid mixture comprising at least one... Agent: Fulbright & Jaworski L.l.p

20080031927 - Solid oral dosage vitamin and mineral compositions: A coating composition comprising a coating agent, a high intensity sweetener, and an acid.... Agent: Philip S. Johnson Johnson & Johnson

20080031929 - Liquid bandage: The present invention relates to hemostatic fabric materials, and to the methods for making and using such materials. In particular, the present invention relates to hemostatic fabric materials made from chemically treated plant materials that are soluble on wound surfaces.... Agent: Kirton & Mcconkie A Professional Corporation

20080031930 - Process for coating a perforated substrate: A process for coating a perforated substrate with a gel (e.g. a polymerised acrylate hydrogel or a xerogel) without substantial occlusion of the perforations comprises (i) forming a layer of a liquid pregel mixture, comprising one or more monomers, on a web coated with a silicone, polyethylene, Teflon® or other... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20080031931 - Organotellurium and selenium-based antimicrobial formulations and articles: The invention provides compositions and methods for treating or preventing the spread of infectious disease through topical or cutaneous contact with a formulation or article containing an organotellurium compound, or an inorganic or organic selenium compound, or formulation thereof, capable of generating superoxide radicals in the presence of an agent... Agent: Wilmerhale/boston

20080031932 - Transdermal atomoxetine formulations and associated methods: Methods and formulations for delivering atomoxetine compounds that minimize drug metabolism and thus increase the effectiveness of the drug are disclosed. The method may include maximizing the in vivo potency of an atomoxetine compound in a subject by transdermally administering the atomoxetine compound to the subject. The in vivo potency... Agent: Thorpe North & Western

20080031934 - Processes for the production of solid dressings for treating wounded tissue: Disclosed are processes for preparing solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen and liquid compositions useful for... Agent: Duane Morris LLP

20080031933 - Transparent transdermal nicotine delivery devices: A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%.... Agent: Philip S. Johnson Johnson & Johnson

20080031937 - Amphoteric liposomes and their use: Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes.... Agent: John C.serio Brown Rudnick Berlack Israels LLP

20080031938 - Biocidal materials for treatment against pathogens: Applicant's present invention is a biocidal material for in vivo use for treatment of pathogenic infections comprising nanoparticles or nanostructures of biocidal material encapsulated within a liposomal carrier... Agent: Akerman Senterfitt

20080031935 - Cholinesterase inhibitors in liposomes and their production and use: The invention relates to a pharmaceutical composition based on an active ingredient that is enclosed in liposomes for topical, transdermal application. The interior of said liposomes comprises an acidic, aqueous medium containing at least one cholinesterase inhibitor, preferably from the group containing donepezil, rivastigmine, galantamine, physostigmine, heptylphysostigmine, phenserine, tolserine, cymserine,... Agent: Popovich, Wiles & O'connell, PA 650 Third Avenue South

20080031936 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20080031939 - Process for the preparation of armodafinil: The invention encompasses processes for preparing intermediates, such as R-modafinic acid or (R)-C1-2 alkyl ester, of modafinic acid, and the conversion of the intermediates to armodafinil.... Agent: Kenyon & Kenyon LLP

20080031940 - Quercetin-containing composition, methods of making, and methods of using: A composition includes 10-50 wt. % quercetin; ≧3 wt. % papain; ≧3 wt. % calcium salt; ≧1 wt. % zinc salt; ≧1 wt. % bee pollen; ≧1 wt. % pumpkinseed; ≧0.5 wt. % bromelain; and 0.1 to 1.5 wt. % saw palmetto; wherein the composition is a sustained release composition... Agent: Dla Piper US LLP Attn: Patent Group

20080031941 - Gastric acid secretion inhibiting composition: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof, an H2 receptor antagonist or a salt thereof and a pharmaceutically acceptable carrier. The dosage form is capable of raising gastric pH to above 4 within two hours after administration... Agent: Morgan Lewis & Bockius LLP

20080031944 - Stabilization of lorazepam: This invention relates to orally disintegrable, lorazepam-containing dosage forms which are storage stable and disintegrable within about 90 seconds or less. In one embodiment, there is provided a storage stable, orally disintegrable dosage form comprising: protected lorazepam particles comprising lorazepam and polymeric material having a glass transition temperature of about... Agent: Cephalon, Inc.

20080031943 - Immediate-release tablet formulations of a thrombin receptor antagonist: Immediate-release formulations for oral administration of a thrombin receptor antagonist are provided. Certain formulations of higher API loading demonstrate sufficient moisture uptake after storage at stressed conditions to retard dissolution. The formulations of the present invention incorporate either lower API loading or elevated disintegrant-to-API ratios, found necessary to achieve disintegration... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080031942 - Solid preparation: A medical drug, in particular, solid preparations containing a medicinal ingredient with high tendency toward gelation, characterized by simultaneously containing a surface modifier and an acid or base. This characteristic realizes improvement to the disintegration easiness, production efficiency and stability of the solid preparations containing the above medicinal ingredient.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080031945 - Gastro retentive delivery system: The present invention is directed to pharmaceutical composition for the manufacture of a gastro retentive drug delivery system comprising a pharmaceutical formulation and an application condition of the same.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080031946 - Low-dose tablets having a network of polymers: The invention relates to low-dose tablets obtained by directly compressing microgranules essentially constituted of a neutral support covered by a polymeric layer containing at least one pharmaceutically acceptable polymer and permitting the modified release of active substances in an aqueous medium, to which an active layer containing at least one... Agent: Buchanan, Ingersoll & Rooney PC

20080031947 - Orally dissolvable/disintegrable lyophilized dosage forms containing protected: The present invention provides an orally dissolvable/disintegrable, lyophilized, dosage form adapted for direct oral dosing, including an active pharmaceutical ingredient (“API”) containing particle which is coated with a lyophilizing solvent protective coating, which protects the form and/or attributes of the particle and/or API, and a matrix. There is also provided... Agent: Cephalon, Inc.

20080031948 - Sustained-release bupropion and bupropion/mecamylamine tablets: Sustained-release bupropion hydrochloride pharmaceutical tablets and combination sustained-release bupropion hydrochloride/mecamylamine hydrochloride pharmaceutical tablets are obtained by granulating the bupropion hydrochloride with a hydroxyalkylcelluose, and blending the resulting granules within an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form,... Agent: Bell, Boyd, & Lloyd LLP

20080031949 - High dose orally dissolvable/disintegrable lyophilized dosage form: The present invention provides an orally dissolvable/disintegrable, lyophilized dosage form including a protected granulate comprising an active ingredient and a protective granulation binder, which substantially protects the form and/or attributes of a granulate and/or active ingredient, and participates in masking bad tasting active ingredients, such as sulfur-containing materials, and a... Agent: Cephalon, Inc.

20080031950 - Novel anelgesic combination: The invention discloses a method of administering a pharmaceutical combination comprising an NSAID and a slow release tramadol to a mammal in need of thereof. This invention further discloses an analgesic combination comprising an NSAID and a slow release tramadol for treating pain and pain related conditions.... Agent: Ramesh Sesha

20080031951 - Compositions and methods for the inhibition of phospholipase a2: The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use.... Agent: Mccarter & English LLP Cityplace I

20080031952 - Nucleic acid comprising a sequence encoding a modified glutenin polypeptide: The present invention is directed to a nucleic acid comprising a sequence encoding a modified glutenin polypeptide, wherein the sequences encoding one or more cysteine residues responsible for intermolecular crosslinking via disulfide bridges were deleted or substituted by sequences encoding other amino acids without amending the reading frame of the... Agent: Arnold & Porter Attn:IPDocketing

20080031953 - Composition and method for treating or preventing psychiatric symptom: The present invention provides a composition comprising precious metal particles for treating or preventing a psychiatric symptom. The composition of the invention is able to improve various psychiatric symptoms and useful for treating or preventing psychiatric disorders.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080031954 - Modulation of angiogenesis by a-beta peptide fragments: Provided are Aβ peptide fragments that are useful in inhibiting angiogenesis. Also provided are methods for the treatment of pathological or unwanted angiogenesis and conditions and diseases associated therewith by administering an effective amount of an Aβ fragment. In a particular embodiment, the peptide fragment includes the sequence HHQKLVFF.... Agent: King & Spalding

20080031961 - Benefit agent containing delivery particle: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, personal care, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080031959 - Anti-migraine oral spray formulations and methods: Formulations of an active pharmaceutical agent suitable for oral spray administration for absorption through the oral mucosa and related methods of preparation and administration are provided. Preferred embodiments provide sumatriptan succinate in a potassium phosphate buffer, wherein when a unit dose volume of about 50 to about 600 mcL of... Agent: Dickstein Shapiro LLP

20080031960 - Antimicrobial mixtures: The present invention presents a mixture comprising charge-stabilized metallic nanoparticles and a photosensitizer, a method for making such mixture, and a method of using such mixture for killing or preventing the growth of microbes.... Agent: Dobrusin & Thennisch PC

20080031956 - Bioimplant formulation: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent comprising lecithin and an organic salt, and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans... Agent: Nixon & Vanderhye, PC

20080031958 - Composition for accelerating bone fracture healing: A composition for accelerating fracture healing, which has a PDE4 inhibitor as an active ingredient, specifically a composition having a PDE4 inhibitor and a biocompatible and biodegradable polymer is provided, which composition, when formulated into a form suitable for local administration such as a microsphere preparation, can provide a pharmaceutical... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080031955 - Product comprising a beta-lactam antibiotic: The present invention relates to a product comprising a β-lactam antibiotic, for instance a cephalosporin, said product containing less than 200 mg of acetone per kg of β-lactam antibiotic. The invention also relates to a process for drying a β-lactam antibiotic, for instance a cephalosporin, said process comprising drying said... Agent: Nixon & Vanderhye, PC

20080031957 - Pulmonary delivery of 1alpha,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin: Pharmaceutical pulmonary compositions, methods of delivery to the lungs of a human and methods of treatment thereof. Pharmaceutical formulations including 1α,25-dihydroxyvitamin D3, an alcohol such as ethanol, and a polyol such as propylene glycol. Another pharmaceutical pulmonary formulation includes 1α,25-dihydroxyvitamin D3 and dry bulking powder, which is used in a... Agent: Quarles & Brady LLP

20080031964 - Combination therapeutic compositions and method of use: The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound of Formula I selected from one or more of betaines, lipidic betaines, betaine lipids and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, .alpha.-glucosidase inhibitors, potassium channel... Agent: Hovey Williams LLP

20080031963 - Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause... Agent: Darby & Darby P.C.

20080031962 - Microencapsulation of cells in hydrogels using electrostatic potentials: Compositions and methods for producing encapsulated cells having an average diameter of less than about 200 μm are provided. Methods for using the disclosed encapsulated cells are also provided... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080031965 - Oral preparations and process for production thereof: Disclosed herein are oral preparations and their production process. The oral preparations are each composed of a complex and a coating composition applied on the complex. The complex has been obtained by dispersing or dissolving a drug having an unpleasant taste and a gastric high-molecular compound in a low melting-point... Agent: Sughrue Mion, PLLC

20080031966 - Sustained release compositions for delivery of pharmaceutical proteins: The present invention provides sustained release compositions that can be manufactured easily while providing long duration of the pharmaceutically useful protein being delivered. The compositions comprise insoluble complexes of the pharmaceutically useful protein and a precipitating agent at an appropriate ratio to achieve a desired sustained release profile. The precipitating... Agent: Nektar Therapeutics

20080031967 - Compositions, products and methods for controlling weight in a mammal: Compositions for controlling mammalian weight, said compositions comprising one or more lipolytic agents for stimulating mammalian lipolysis and/or thermogenic agents for modulating mammalian thermogenesis. Products, consumer and otherwise, comprising said compositions and methods of using both the present compositions and products to control mammalian weight.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080031968 - Methods for increasing cellular energy expenditure: The present invention is directed to methods of treating a human for a variety of conditions by administering an agonist of the G protein coupled receptor TGR5. In addition, the invention includes methods for determining whether a test compound is likely to be effective in treating one of these conditions... Agent: Law Office Of Michael A. Sanzo, LLC

20080031969 - Composition for treating psoriasis: The present invention relates to a composition and methods or uses thereof in the prophylaxis and treatment of psoriasis and other auto-immune inflammatory disorders. The composition may be comprised of TGF-β1, TGF-β2, and dairy derived proteins comprising a large proportion of β-lactoglobulin.... Agent: Ogilvy Renault LLP

20080031970 - Method of promoting natural bypass: An angiogenic factor comprising a mixture of proteins derived from bone. The angiogenic protein mixture is produced by a series of steps that allow the proteins to be kept in solution. The angiogenic mixture of bone proteins is produced by a multi-step process that includes at least one ultrafiltration step,... Agent: Williams, Morgan & Amerson

20080031972 - Process for manufacturing spherical activated carbon: A process for manufacturing a spherical activated carbon, characterized by comprising the steps of: (1) forming a spherical substance of a heat-fusible resin, (2) oxidizing the spherical substance of a heat-fusible resin to form a heat-infusible spherical substance, and (3) activating the heat-infusible spherical substance to form the spherical activated... Agent: Reed Smith LLP

20080031971 - Use of xenon for the prevention of programmed cell death: Described is the use of xenon for preventing or reducing cellular death, preferably aberrant apoptosis. Preferred embodiments relate to the use of xenon for preventing (a) cellular damage for tissue and organs to be transplanted, (b) apoptotic cell death after eye laser surgery, and (c) for protecting endothelial cells of... Agent: Wilson Sonsini Goodrich & Rosati

20080031973 - Means of improving hand grip: An antislip agent directly applicable to the hands for a short-term negation of the effects of perspiration on grip security. The hands will also become slightly sticky for 1 to 2 minutes upon use, after which time the effect of this invention will disappear, allowing one to then decide whether... Agent: Soon M. Lee

20080031974 - Composition and process for removing and preventing mildew and fungal growth: This invention comprises a composition and the process of using the composition for removing and preventing mold, mildew, and fungal growth. The composition comprises at least one alkali metal perborate, at least one inhibiting compound selected from the group consisting of alkali metal silicates, triazoles and mixtures thereof in any... Agent: Naval Air Warfare Center Aircraft Division Office Of Counsel Bldg 435

20080031975 - Copper lowering treatment of inflammatory and fibrotic diseases: The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention... Agent: Casimir Jones, S.c.

20080031976 - Multivitamin formulations for promoting healthy collagen, and methods of their use: Described are vitamin and mineral formulations comprising folic acid compound in amounts to promote healthy collagen, and optionally other vitamins and minerals such as vitamin B6, vitamin B12, calcium, magnesium, boron, as well as methods of administering such formulations to promote healthy collagen, to treat or prevent collagen-related conditions, and... Agent: Kagan Binder, PLLC

20080031977 - Pharmaceutical compositions comprising cannabigerol: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.... Agent: Wolf Greenfield & Sacks, P.C.

20080031978 - Compositions and methods for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders: Compositions, kits and methods are provided for promoting brain and cardiovascular health, preventing or treating neurological and vascular disorders. In one embodiment, the composition comprises Rhodiola rosea (root), Ginkgo biloba (leaf), Panax notoginseng (root), and Ligusticum chuanxiong (rhizome). The composition can be used as pharmaceuticals or nutraceuticals for promoting general... Agent: Wilson Sonsini Goodrich & Rosati

20080031979 - Use of extracts for the treatment of viral disorders: The present invention relates to plant extracts and compositions containing such plant extracts useful in the treatment of viral disorders, including but not limited to the treatment of viral lesions resulting from viruses such as Herpes Simplex virus.... Agent: Philip S. Johnson Johnson & Johnson

20080031980 - Curcumin-containing composition, methods of making, and methods of using: A composition includes 50-80 wt. % of at least one curcumin compound, 10-50 wt. % quercetin, ≧3 wt. % papain, and ≧3 wt. % bromelain, wherein the composition is suitable for oral administration to a human. Methods of making and using the composition are provided.... Agent: Law Office Of John K. Pike, PLLC

20080031981 - Cosmetic composition containing an extract of limnocitrus littoralis: The invention relates to a cosmetic composition, characterized in that it contains, as active agent, an extract of Limnocitrus littoralis obtained by extraction with an extraction solvent selected from the group comprising alcohols and aqueous-alcoholic mixtures, in a cosmetically acceptable vehicle compatible with topical application. It further relates to a... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080031982 - Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on tetrahydro-isoalpha acids, commonly found in hops.... Agent: Mcdermott Will & Emery LLP

20080031985 - Annatto extract compositions, including geranyl geraniols and methods of use: Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal... Agent: Kirk Hahn

20080031984 - Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer: The present invention provides methods for preventing colon cancer by administering, to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to prevent colon cancer, which composition inhibits COX-2. The present invention also provides methods for treating inflammation locally... Agent: King & Spalding

20080031983 - Method for treatment of constipation-predominant irritable bowel syndrome: The present invention provides methods for treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat constipation-predominant irritable bowel syndrome (c-IBS). Treatment of c-IBS includes the treatment of the constipation... Agent: King & Spalding

20080031986 - Protein kinase modulation by hops and acacia products: Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.... Agent: Mcdermott Will & Emery LLP